Document:

EX-10.3

  

 Exhibit 10.3 

CRUCELL HOLLAND B.V. – VASCULAR BIOGENICS LTD. 

COMMERCIAL GENE THERAPY LICENSE AGREEMENT 

  
 Portions of this
exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

 COMMERCIAL GENE THERAPY LICENSE AGREEMENT 

This Commercial Gene Therapy License Agreement (“Agreement”) is made and entered into on April 15, 2011 (“EFFECTIVE DATE”) by and
between: 
 CRUCELL HOLLAND B.V., a corporation organized under the laws of the Netherlands, having offices located at Archimedesweg 4, 2333 CN,
Leiden, the Netherlands “CRUCELL”) 
 and 

VASCULAR BIOGENICS Ltd., with offices located at 6 Jonathan Netanyahu Street, 60376, Or-Yehuda, Israel (hereinafter referred to as “VBL” or
“LICENSEE”), 
 the parties hereinafter individually referred to as “Party” and collectively as “Parties”. 

PREAMBLE 
  

	 	•	 	WHEREAS, CRUCELL is the owner of a PER.C6® cell line and of the associated information, know-how, and patents rights (as defined below); 

 

	 	•	 	WHEREAS, LICENSEE is engaged in the business of biomedical research, and the manufacturing, testing and commercializing of pharmaceutical products and services; 

 

	 	•	 	WHEREAS, LICENSEE and CRUCELL are parties to a Research License and Option Agreement dated March 24, 2005, granting LICENSEE the rights to conduct research under the PER.C6® PATENTS and to utilize PER.C6® KNOW HOW (as such terms are defined below) to prepare and evaluate gene therapeutics based on adenoviral
vectors, and an option for a commercial license; 

  

	 	•	 	WHEREAS, LICENSEE has exercised its option to a commercial license and the Parties have negotiated an agreement for commercial rights under the terms and conditions as set forth hereinafter; 

NOW, THEREFORE, in consideration of the mutual covenants and promises set forth herein, the Parties, intending to be legally bound, agree as follows:

  

	1.	DEFINITIONS 

 Plural used in this Agreement shall mean singular and vice versa. 

 

	 	1.1.	AFFILIATE means any person, corporation, organization or other legal entity which, directly or indirectly, controls, or is controlled by, or is under common control with, a Party. CONTROL shall mean the ability,
directly or indirectly, to direct the activities of the relevant entity, including the ownership or holding (directly or indirectly) of fifty percent (50%) or more of (i) the securities or other ownership interests representing the equity,
the voting stock or general partnership interest, or (ii) the rights to elect or appoint directors (or other governing body). 

  

	 	1.2.	APPROVED COUNTRIES means the countries mentioned in Exhibit 1.2 

  

	 	1.3.	BMF means the PER.C6® Biologics Master File as filed with the United States Food and Drug Administration 

 

	 	1.4.	EFFECTIVE DATE has the meaning set forth in the first paragraph of this Agreement. 

  

	 	1.5.	FIELD means the treatment of cancer in human by administering to a subject an adenoviral vector including, but not limited to, therapeutic gene sequence(s), the therapeutic effect of which is principally caused by the
expression product of said gene sequence(s) and will not serve as a vaccine. 

  
 1 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

	 	1.6.	FIRST COMMERCIAL SALE means the first sale of a PRODUCT in a country by LICENSEE or any of its SUBLICENSEES OR REGISTERED AFFILIATES. 

 

	 	1.7.	FUNCTIONAL GENOMICS means the identification and/or validation of the biological function(s) of human and animal genes, and/or gene fragments and/or proteins and/or fragments of proteins transcribed from such genes, by
means of the construction and use of arrayed collections of said genes and/or gene fragments, in non-phage viral vectors, to enable the identification and validation of drug targets, nutriceuticals and/or protein therapeutics, for the treatment or
prevention of human or animal disease(s) and/or the maintenance of nutritional health. 

  

	 	1.8.	GOVERMENTAL AUTHORITIES means the FDA and other foreign governmental equivalents. 

  

	 	1.9.	IMPROVEMENT KNOW HOW RIGHTS means know how rights owned or licensable by LICENSEE or its REGISTERED AFFILIATES, which are developed during the Term using the technology claimed by the IMPROVEMENT PATENT RIGHTS, and
which (i) come into the possession of LICENSEE or its REGISTERED AFFILIATES during the course of PROGRAMS and during the TERM of this Agreement, (ii) are not generally known, (iii) are related to the subject matter(s) of the
IMPROVEMENT PATENT RIGHTS and are necessary for CRUCELL’s practice of the IMPROVEMENT PATENT RIGHTS as permitted under Section 2.5, and (iv) are not subject to a good faith reasonable third party confidentiality obligation that
prevents the disclosure of the same. 

  

	 	1.10.	IMPROVEMENT PATENT RIGHTS means any patent issued after the EFFECTIVE DATE only to the extent that it claims (i) a new use of the PACKAGING CELLS including a generic product by process using said cells,
(ii) an improved cell line derived from the PACKAGING CELLS, (iii) culturing or processing of PACKAGING CELLS, or (iv) a new use of an improved cell line described in clause (ii) of this sentence, in each case that is developed
during the course of PROGRAMS under this Agreement. 

  

	 	1.11.	MODIFIED CELLS means PER.C6® CELLS modified by incorporating therein VBL TECHNOLOGY, but excluding the integration thereof into the genome of the PER.C6® CELL. 

  

	 	1.12.	NET Sales means the gross amount invoiced on sales of the PRODUCTS by LICENSEE, SUBLICENSEES, REGISTERED AFFILIATES and/or their respective sub-licensees to customers, less the following deductions related to the sale
and delivery of PRODUCTS: (i) any commercially reasonable credits and allowances, repayments or adjustments granted or made to customers; (ii) any commercially reasonable trade or cash discounts, rebates, charge-backs or administrative
fees or other price reductions granted to customers; and (iii) any sales, transportation, import, export or other like taxes, duties and government charges (but specifically excluding any taxes based on net income imposed upon the sale of the
PRODUCTS) to the extent included in the gross sales price, wherein rebates, charge-backs, administrative fees and sales or other like taxes are actually paid or incurred by LICENSEE, SUBLCENSEES, REGISTERED AFFILIATES and/or their respective
sub-licensees. A sale of the Product to third party customers shall also include a transfer or other disposition for consideration other than case, in which case such consideration shall be valued at the fair market value thereof. 

 

	 	1.13.	NON-APPROVED COUNTRIES means any countries other than APPROVED COUNTRIES. 

  

	 	1.14.	 PACKAGING CELLS means PER.C6® CELLS and MODIFIED CELLS.

  
 2 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

	 	1.15.	PACKAGING CELL-EXPRESSION SEQUENCE means (i) any recombinant DNA sequence used by LICENSEE, or expression product or any alteration or modification thereof, derived from or obtained by, or produced using PACKAGING
CELLS; or (ii) a fragment of any recombinant DNA sequence or expression product derived from obtained by, or produced using PACKAGING CELLS, and (iii) provided that (i) and (ii) are based upon and/or are derived from VBL
TECHNOLOGY in combination with the genome of a serotype 5 human adenovirus. 

  

	 	1.16.	PACKAGING CELL KNOW HOW means PER.C6® KNOW HOW, MODIFIED CELLS and all materials, information, experience and data, formulae, procedures, results and
specifications, regulatory filings and clinical and pre-clinical data, in written or electronic form, which are specifically related to MODIFIED CELLS, which (i) are in the possession of the Parties at the EFFECTIVE DATE or come into the
possession of the Parties during the TERM of this Agreement, (ii) are not generally known (iii) are necessary for the research use of the MODIFIED CELLS, and (iv) are not subject to a third party confidentiality obligation that
prevents either Party from disclosing the same. 

  

	 	1.17.	PATENT means granted patents, including utility models and certificates of I vention, and reissues, reexaminations, supplementary protection certificates, extensions, and term restorations thereof, and patent
applications therefor, including any continuations, continuations-in-parts, and/or divisionals applications thereof, and any and all patents issuing from any of the above. 

 

	 	1.18.	PER.C6® CELL LINE or PER.C6® CELL means the cells deposited under ECACC No. 96022940, as described
in Exhibit 1.15, as updated by CRUCELL from time to time in accordance with Section 3 below to include additional CELLS deposited following the EFFECTIVE DATE. 

 

	 	1.19.	PER.C6® KNOW HOW means PER.C6® CELLS and all materials, information, experience and data, formulae,
procedures, processes and techniques, results and specifications, know-how, regulatory filings and clinical and pre-clinical data, which are specifically related to PER.C6® CELLS, and which
are described in the PER.C6® KNOW HOW FILE, as updated by CRUCELL from time to time in accordance with Section 3 below. 

 

	 	1.20.	PER.C6® KNOW HOW FILE means the written compilation of PER.C6® KNOW HOW and PACKAGING CELL KNOW HOW,
which is provided to all PER.C6® licensees, and which includes but it not limited to processing and manufacturing information and data limited to using PER.C6® CELLS and/or MODIFIED CELLS for the production of replication defective adenoviral vectors therewith. 

  

	 	1.21.	PER.C6® PATENTS mean PATENTS that CRUCELL owns, or controls by license or otherwise, wherein said license has a sublicense right, or which CRUCELL has a right to
assignment, and that claim PER.C6® CELLS or the use thereof for the manufacture of replication defective adenoviral vectors, identified on Exhibit 1.21. 

 

	 	1.22.	PRODUCT means a pharmaceutical product, intended for administration to human subjects, comprising of PACKAGING CELL-EXPRESSION SEQUENCE, in final finished form. 

 

	 	1.23.	PROGRAMS means research and development programs of LICENSEE or its SUBLICENSEES in the FIELD to develop PRODUCT in the FIELD, including but not limited to any and all pre-market-registration activities and
post-market-approval studies. 

  

	 	1.24.	REGISTERED AFFILIATE means an AFFILIATE operating in APPROVED COUNTRIES to the extent identified in Exhibit 1.24 from time to time in accordance with the provisions of Section 2.1.5 below, providing full
details of the name, offices and branches of such AFFILIATE or STRATEGIC PARTNER. 

  
 3 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

	 	1.25.	STRATEGIC PARTNER means a reputable company with whom VBL has entered into a collaboration agreement for the co-development and / or co-marketing of pharmaceutical products, substantially discovered, researched or
developed by VBL in the FIELD which either (i) enters into a material transfer agreement with CRUCELL substantially in the form of Exhibit 1.25 hereto, or (ii) does not obtain access to the PACKAGING CELLS. 

 

	 	1.26.	SUBLICENSEE means a REGISTERED AFFILIATE to which LICENSEE grants a sublicense under and in accordance with this Agreement. 

  

	 	1.27.	TERM starts on the EFFECTIVE DATE and continues as described in Section 7.1. 

  

	 	1.28.	THIRD PARTIES means any person or entity other than VBL, CRUCELL, SUBLICENSEES, AFFILIATES or STRATEGIC PARTNER. 

  

	 	1.29.	VALID PATENT CLAIM shall mean a claim in any issued and unexpired PER.C6® PATENT, which claim has not been held invalid by a non-appealed or unappealable decision
by a court or other appropriate body of competent jurisdiction, provided, however, that there exists no outstanding order, injunction or other action (including any temporary relief) that impairs the rights granted under such CLAIM by
LICENSEE, its SUBLICENSEES or REGISTERED AFFILIATES, as contemplated under this Agreement. For the purpose of royalty determination and payment, any claim being prosecuted in a pending patent application in a particular country shall be deemed to be
a VALID PATENT CLAIM provided such claim is not pending for more than ten (10) years from the earliest filing date to which the patent application is entitled to claim in such country (such as the first filed application based on a PCT
application and claiming the PCT filing date, or the first national patent application from which subsequent patent applications claim filing date benefit) and in which case it shall cease to be considered a VALID PATENT CLAIM until a patent in the
pertinent country based on such application is granted. 

  

	 	1.30.	VTSTM TECHNOLOGY means LICENSEE’s proprietary VTSTM (Vascular Targeting System) platform technology that enables control of gene expression to areas in which angiogenesis is taking place to either promote
or destroy newly formed blood vessels. 

  

	 	1.31.	VBL PROPRIETARY RIGHTS shall mean, as between the Parties, all right and title in and to VBL TECHNOLOGY, LICENSEE’S INFORMATION, PACKAGING CELL-EXPRESSION SEQUENCE and PRODUCTS, including without limitation
(i) all data, results, inventions, know-how, improvements, developments or other information arising from or in connection with the PROGRAM; and (ii) any applications, improvements, modifications and derivatives of any of the above and any
know-how, proprietary rights and PATENTS relating thereto or arising therefrom. 

  

	 	1.32	VBL TECHNOLOGY shall mean, as between the Parties, replication-deficient E1-and E3-deleted adenoviral 5 vector or adenovirus 3 vector and conditionally replicative adenovirus (CRAD) 3 and 5 Vector, containing either the
FAS-Chimera transgene or Tyrosine Kinase and VTSTM TECHNOLOGY, and any know how related thereto and to the use thereof. At any time during the TERM, LICENSEE may provide CRUCELL with written notice of its wish for the transgene to be changed.
Such change shall be deemed effective unless CRUCELL responds to LICENSEE’s notice within thirty (30) days of its receipt that is withholding consent, provided such consent may only be withheld if such change would result in a technology
which is either (i) directly competitive with another technolofy under a then existing exclusive out-license by CRUCELL, or (ii) infringes any CRUCELL’s patent which are not otherwise covered in this Agreement. For the avoidance of
doubt VBL technology will contain only one (1) Transgene in combination with aforementioned either Adenovirus 3 or 5 or (CRAD) and VTSTM TECHNOLOGY. 

  
 4 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

	2.	LICENSES; SUBLICENSING; OWNERSHIP OF CERTAIN RIGHTS; GRANT BACK LICENSE 

  

	 	2.1.	CRUCELL Grant to LICENSEE. 

  

	 	2.1.1.	CRUCELL hereby grants to LICENSEE, a non-exclusive, worldwide license, under the PER.C6® PATENTS and
PER.C6® KNOW HOW, without the right to grant sublicenses except to SUBLICENSEES in accordance with the provisions of Section 2.1.4 below, (1) to use and import PER.C6® CELLS and PER.C6® KNOW HOW for the sole purpose of making MODIFIED CELLS during the course and performance of PROGRAMS; and (2) to
use and import MODIFIED CELLS and PACKAGING CELL KNOW HOW during the course and performance of PROGRAMS; and (3) to use and import PACKAGING CELLS and PACKAGING CELL KNOW HOW to manufacture and to have made, in facilities of LICENSEE or its
SUBLICENSEES subject to Section 2.4 below, PRODUCTS for use in the FIELD. For the avoidance of doubt, and subject to such third party entering first into a Material Transfer Agreement with CRUCELL prior to the transfer of any PACKAGING CELLS or
PACKAGING CELL KNOW HOW, LICENSEE is also granted hereunder the right to provide PACKAGING CELLS, PACKAGING CELL KNOW-HOW and PRODUCTS to third parties for bona fide contract service purposes in the course and performance of PROGRAMS and for the
manufacture and making of PRODUCTS solely on LICENSEES’ behalf. 

  

	 	2.1.2.	CRUCELL hereby grants to LICENSEE, a non-exclusive, worldwide license, under the PER.C6® PATENTS and
PER.C6® KNOW HOW, with the right to grant sublicenses, to develop, use, import, offer to sell, and sell PRODUCTS for use in the FIELD. 

 

	 	2.1.3.	Sublicense Requirements in General. Any agreement in which LICENSEE purports to sublicense the rights granted herein under the PER.C6® PATENTS and PER.C6® KNOW HOW, (i) shall not grant any further right to sublicense under the PER.C6® PATENTS and PER.C6® KNOW HOW nor grant any right to transfer the PER.C6® KNOW HOW or the sublicensed rights; and (ii) shall include terms at least as
restrictive as those contained in this Agreement with respect to the use and exploitation of the rights granted under the PER.C6® PATENTS and
PER.C6® KNOW HOW. 

  

	 	2.1.4.	 Certain Sublicense Requirements – REGISTERED AFFILIATES. LICENSEE shall be permitted to sublicense its rights and obligations pursuant to
Section 2.1.1 to REGISTERED AFFILIATES (without the right to further sublicense), provided each such REGISTERED AFFILIATE acknowledges and assumes all of the rights, restrictions and obligations of this Agreement applicable to such
SUBLICENSEE hereunder, except, as between the Parties, for those rights and obligations for which LICENSEE shall be solely responsible as provided for herein (e.g. indicated by wording such as “on its own behalf and on behalf of its
SUBLICENSEES”), in a writing signed by a duly authorized representative of such REGISTERED AFFILIATE. LICENSEE shall be responsible for assuring that each REGISTERED AFFILIATE has become fully aware of, and complies with, its rights,
restrictions and obligations under this Agreement as a SUBLICENSEE prior to such REGISTERED AFFILIATE exercising any right that LICENSEE may sublicense to such REGISTERED AFFILIATE hereunder. Irrespective of any written sublicense to a REGISTERED
AFFILIATE, the exercise of any sublicenseable right hereunder by a REGISTERED 

  
 5 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

	 	
AFFILIATE shall be deemed to bind such REGISTERED AFFILIATE to comply with the applicable restrictions, obligations and duties hereunder, except for those obligations and duties for which
LICENSEE is solely responsible as provided herein. Irrespective of the number of SUBLICENSEES, CRUCELL shall only be required to communicate with, and provide technical assistance to, LICENSEE, or one designated SUBLICENSEE, unless the Parties agree
otherwise in a written and duly executed amendment hereto. LICENSEE and its REGISTERED AFFILIATES shall be jointly and severally liable towards CRUCELL for their compliance with the restrictions, obligations and duties hereunder. 

 

	 	2.1.5.	At any time during the TERM, LICENSEE may provide CRUCELL with written notice of its wish for a new AFFILIATE to become a REGISTERED AFFILIATE. If Parties agree in writing that such AFFILIATE shall become a REGISTERED
AFFILIATE, such AFFILIATE shall be included in Exhibit 1.20, by way of a duly executed written amendment, after CRUCELL has received the document duly executed by the respective AFFILIATE as referred to in Section 2.1.4. CRUCELL shall respond
to LICENSEE’s notice within fourteen (14) days of its receipt, and shall not unreasonably withhold its consent to the addition of an Affiliate as aforesaid. 

 

	 	2.1.6.	The license grant in this Section 2 shall be effective from the date that CRUCELL receives the License Fee specified in Section 4 herein until expiration of the TERM. 

 

	 	2.2.	Restricted Access to PACKAGING CELLS 

 The licenses grant herein is restricted such that
LICENSEE and its SUBLICENSEES shall not be permitted under the terms of this Agreement to engage in the following activities: 
  

	 	2.2.1.	to use PACKAGING CELLS (i) in or for FUNCTIONAL GENOMICS studies, (ii) for the manufacture of RECOMBINANT PROTEIN, (iii) in or for the manufacture of vaccines against communicable infectious agents, or
(iv) in or for the development of products to prevent or treat diseases caused by chicken anemia virus, or to produce vectors, or expression products thereof, containing all or a part of a chicken anemia virus gene; 

 

	 	2.2.2.	to use, store, hold or otherwise deliver PACKAGING CELLS or PACKAGING CELL KNOW HOW in or to NON-APPROVED COUNTRIES; 

  

	 	2.2.3.	to offer, provide, give access to or to otherwise make available to third parties or to AFFILIATES that are not SUBLICENSEES, PACKAGING CELLS and/or PACKAGING CELLS KNOW HOW, except as provided for in Section 2.3
and 2.4 below; 

  

	 	2.2.4.	to offer or provide services to third parties, or to AFFILIATES that are not SUBLICENSEES, relating to or using PACKAGING CELLS and/or PACKAGING CELLS KNOW HOW. 

 

	 	2.3.	 Permitted Access to PACKAGING CELLS. Sections 2.2.3 and 2.2.4 shall not apply to the extent that LICENSEE or its REGISTERED AFFILIATES will be
required to provide, give access to or otherwise make available, by order or regulation of a governmental agency or court of competent jurisdiction, the results, materials, or know how obtained in the course of PROGRAMS, or incorporating

  
 6 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

	 	
PACKAGING CELLS or PACKAGING CELL KNOW HOW, or the sale and/or distribution of PRODUCTS. Under such circumstances, LICENSEE shall promptly notify CRUCELL of such order or regulation requiring
disclosure and shall make its best efforts to cooperate with CRUCELL to preserve the confidentiality of, and CRUCELL’s proprietary interest in, the PACKAGING CELL KNOW HOW. 

 

	 	2.4.	Supply of PACKAGING CELLS to Contractors. 

  

	 	2.4.1.	Subject to the conditions stated in this Section, LICENSEE shall have the right to deliver to a fee-for-service contractor (“Contractor”), PACKAGING CELLS and PACKAGING CELL KNOW HOW (1) to conduct
authorized studies of and other tasks relating to PACKAGING CELLS, solely for use by LICENSEE in PROGRAMS, and/or (2) to use PACKAGING CELLS and PACKAGING CELL KNOW HOW to develop processes and perform other tasks for the manufacture and making
of, and to manufacture and make, PACKAGING CELLS and PRODUCTS. LICENSEE shall not provide PACKAGING CELLS or PACKAGING CELL KNOW HOW to a fee-for-service Contractor except pursuant to a completely executed, written PER.C6® Material Transfer Agreement (“MTA”) with CRUCELL. The Contractor shall enter into a material transfer agreement substantially in the form of Exhibit 2.4.1 hereto. 

 

	 	2.4.2.	CRUCELL shall have the right to disapprove the choice of any fee-for-service third party that is not reputable and/or reliable or operates in a NON-APPROVED COUNTRY, which disapproval shall only be asserted reasonably
and upon prompt notice to LICENSEE of no later than fourteen (14) days following receipt of such Contractor’s details with reference specifically to this section, setting forth the reasons for CRUCELL’S disapproval. For purposes of
this Section 2.4.2, “not reputable and/or reliable” shall mean, by way of example, that such fee-for-service third party is located in a country or jurisdiction where CRUCELL has reason to believe in good faith (a) does not
provide adequate protection for intellectual property and proprietary information or (b) does not provide adequate judicial recourse in case of misappropriation or misuse of intellectual property or proprietary information. Countries or
jurisdictions that are on the U.S. Trade Representative’s annual “Special 301” Watch List shall be deemed to qualify as countries or jurisdictions that do not provide adequate protection or recourse as referred to under (i)(a) and
(i)(b) above. CRUCELL has pre-approved on Exhibit 2.4.2 the third party contractors listed therein. 

  

	 	2.5.	Ownership of Certain Rights; Grant Back License 

  

	 	2.5.1.	Except where expressly stated otherwise in this Agreement to the contrary, CRUCELL shall have no right, title and interest in and to any VBL PROPRIETARY RIGHTS (including any right to be notified thereof), provided that
LICENSEE may notify CRUCELL of such information from time to time, at its sole discretion. 

  

	 	2.5.2.	LICENSEE and its REGISTERED AFFILIATES hereby agree to grant to CRUCELL a perpetual, royalty-free, non-exclusive worldwide license, with the right to sublicense, under the IMPROVEMENT PATENT RIGHTS and IMPROVEMENT KNOW
HOW RIGHTS, provided that the license right under this Section shall not extend to the manufacture, use or sale of the particular PACKAGING CELL- EXPRESSION SEQUENCE(S) and/or PRODUCT(S) or the VBL Technology that are developed by LICENSEE or
its SUBLICENSEES and that are the subject of this Agreement or the VBL PROPRIETARY RIGHTS. 

  
 7 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

	3.	SUPPLY OF CELLS AND KNOW-HOW; CERTAIN UPDATES; TECHNICAL ASSISTANCE; REPORTING 

  

	 	3.1.	Supply of Cells and Know-How. Within thirty (30) days after receipt of the License Issuance Fee payment under Section 4.1.1, CRUCELL shall disclose and transfer to LICENSEE PER.C6® CELLS and the PER.C6® KNOW HOW that is incorporated into the most recent version of the
PER.C6® KNOW HOW FILE. 

  

	 	3.2.	Updates. During the TERM, CRUCELL shall promptly provide updates (i) of the PER.C6® KNOW HOW FILE to LICENSEE as it is revised and made available to
all or substantially all PER.C6® licensees or to PER.C6® licensees conducting activities or granted rights similar to those contained
in this Agreement, including without limitation new uses in the Field of PER.C6® CELLS and KNOW HOW, improved and updated techniques and know-how for the use of PER.C6® CELLS and PER.C6® LOW HOW, and any known problems relating to the use of PER.C6®
CELLS and PER.C6® KNOW HOW or deviations from previously provided information, all as may be applicable to the license granted to LICENSEE hereunder and (ii) of any safety or regulatory
concerns that come to CRUCELL’s attention relating to the PACKAGING CELL and PACKAGING CELL KNOW HOW. 

  

	 	3.3.	Technical Assistance. During the TERM, CRUCELL shall provide reasonable technical assistance (including guidance on know how related to the work with the
PER.C6® CELLS) to LICENSEE, as may be necessary to use PACKAGING CELLS and PACKAGING CELL KNOW HOW in PROGRAMS, upon reasonable request and free of any additional cost to LICENSEE. To support
the KNOW HOW transfer, LICENSEE shall be entitled, upon reasonable notice to CRUCELL, to visit CRUCELL’s facilities from time to time, but no more than five (5) days, once a year and view the production of the PER.C6® CELLS and other relevant processes and techniques relating to the making of MODIFIED CELLS, as well as to receive answers from CRUCELL’s employees regarding the use of such cells and of the
PACKAGING CELL KNOW HOW, to the extent necessary for the purposes of a PROGRAM. LICENSEE shall compensate CRUCELL for technical assistance in excess of two (2) man-day visits by CRUCELL technical personnel to LICENSEE’s facilities, on an
annual basis, for the first two (2) years of the TERM, on reasonable terms to be agreed in advance. A third man-day visit (or more) shall be at no additional cost if LICENSEE reports a material deviation from established PER.C6 KNOW HOW
performance parameters, which deviation report requires such third man-day of technical assistance. 

  

	 	3.4.	Access and Reference to BMF; Conduct of Registration and Testing. 

  

	 	3.4.1.	 LICENSEE and its REGISTERED AFFILIATES acknowledge that the BMF is owned by CRUCELL, may be filed by CRUCELL with other foreign governmental
equivalent to the FDA and is confidential and of crucial importance to the Parties as well as to all other licensees of PER.C6® CELL technology. LICENSEE and its REGISTERED AFFILIATES shall
have the right to review CRUCELL’s copy of the BMF filed with the FDA and other Governmental Authorities after providing CRUCELL with thirty (30) days prior notice. LICENSEE has the right to cross-reference the BMF as may be required for
any regulatory submissions to Governmental Authorities, and upon 

  
 8 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

	 	
LICENSEE’ request CRUCELL shall (i) notify the FDA (with a copy to LICENSEE) that LICENSEE is authorized to reference the data within the BMF; and (ii) provide LICENSEE with any
and all existing BMF documentation in the possession of CRUCELL (provided that CRUCELL is legally able to do so) in so far required to support any regulatory submission LICENSEE makes to a Governmental Authority in a country where a BMF or its
foreign equivalent has not been submitted or is not in effect or may not be referenced to. CRUCELL shall notify LICENSEE of any significant update to the BMF from time to time and shall provide LICENSEE with a copy thereof upon its request as set
forth above. 

  

	 	3.4.2.	LICENSEE and its REGISTERED AFFILIATES shall not be entitled to, and agree that they will not, characterize, or issue releases or certificates of analysis for, or analyze the genome of, any PACKAGING CELLS, or engage in
any research of PACKAGING CELLS that concern any safety, toxicity or tumorgenicity of PACKAGING CELLS without obtaining the prior written agreement of CRUCELL, provided that, if any Governmental Authority requests additional data or characterization
of PACKAGING CELLS that CRUCELL chooses not to provide LICENSEE shall have the right to perform its own studies solely as required by the Governmental Authority, and to provide the results to the requesting Governmental Authority. Failure by CRUCELL
to provide LICENSEE with such information or data for delivery to the applicable Governmental Authority within a reasonable period shall be deemed as CRUCELL choosing not to provide same. The aforementioned restrictions shall only apply with respect
to PACKAGING CELLS, and not PACKAGING CELL-EXPRESSION SEQUENCE or PRODUCT, the analysis of which shall be at the sole discretion of LICENSEE and not subject to any approval of CRUCELL. 

 

	 	3.4.3.	LICENSEE further agrees to use its reasonable efforts to promptly notify CRUCELL of any and all communications to and from Governmental Authorities directly relating to the safety of PACKAGING CELLS and agrees to
consult promptly with CRUCELL to resolve any such concerns with the FDA or such other Governmental Authorities, Noncompliance by LICENSEE with the obligation to use its reasonable efforts to obtain prior agreement of CRUCELL prior to any
characterization, release or certificate issuances of PACKAGING CELLS as set forth in Section 3.4.2 above, or to promptly notify and consult with CRUCELL in its efforts to resolve any such issues with the FDA or other Governmental Authorities
as set forth in this Section 3.4.3 shall be considered to constitute a failure to comply with a material condition or covenant of this Agreement to which Section 6.5 herein applies. 

 

	 	3.5.	Reporting. 

  

	 	3.5.1.	LICENSEE, on its own behalf and on behalf of its SUBLICENSEES, shall keep CRUCELL informed on a bi-yearly (six(6)-month) basis about (1) any communication with Regulatory Authorities about PACKAGING CELLS, and
(2) results of any testing performed on the PACKAGING CELLS. A template for use in complying with the quarterly reporting obligation is attached as Exhibit 3.5.1. 

 

	 	3.5.2.	 LICENSEE, on its own behalf and on behalf of its SUBLICENSEES, shall keep CRUCELL informed on an annual basis, on or before the anniversary of the
EFFECTIVE DATE, with a detailed report of the 

  
 9 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

	 	
data relating specifically to PACKAGING CELL performance, PACKAGING CELL KNOW HOW, as well as the operating, culturing and manufacturing parameters and data resulting from its use of the
PACKAGING CELL during the course of the PROGRAM. To facilitate the mutually beneficial resolution of any PACKAGING CELL technical performance issue, if any, LICENSEE hereby agrees to discuss with CRUCELL technical personnel relevant technical data
to assist in resolving such issues. A template for use in complying with the annual reporting obligation is attached as Exhibit 3.5.2. 

  

	 	3.5.3.	It is agreed and understood that LICENSEE shall not be obligated to disclose any information, data or know-how relating to VBL PROPRIETARY RIGHTS unless and to the extent it is related to PACKAGING CELLS and/or their
use hereunder. In such event, any and all disclosed information, data or know-how shall not be used or disclosed without LICENSEE’s prior written consent, which consent may be withheld at its sole discretion. 

 

	 	3.5.4.	LICENSEE, on its own behalf and on behalf of its SUBLICENSEES, shall promptly notify CRUCELL in writing of any substantial deviations from established PER.C6®
CELL characteristics and/or performance parameters included in PER.C6® KNOW HOW, prior to any notification by LICENSEE or its SUBLICENSEES to any other entity other than to the appropriate
Regulatory Authorities such as the FDA. 

  

	 	3.5.5.	Subject to the provisions of Section 3.5.3, information reported to CRUCELL pursuant to Sections 3.5.1 through 3.5.4 may be used by CRUCELL to assist LICENSEE in the successful implementation of PACKAGING CELL KNOW
HOW, resolving technical and regulatory issues respecting PACKAGING CELL and the BMF, to amend and/or annotate the collection of PER.C6® KNOW HOW for delivery to PER.C6® licensees and/or to update the BMF, which PER.C6® KNOW HOW and BMF shall only be disclosed under conditions of confidentiality. Except as
expressly in Sections 2.5.2, 2.5.3 and 2.5.4 above, CRUCELL shall not use any information or know-how relating to PRODUCT(S) or PACKAGING CELL EXPRESSION SEQUENCE(S) that are developed by LICENSEE or its SUBLICENSEES, or relating to any VBL
PROPRIETARY RIGHTS, nor disclose any of the above to any licensee or other third party (including any Regulatory Authority) without the prior written consent of LICENSEE, which consent may be withheld at its sole discretion. 

 

	4.	LICENSE FEES 

  

	 	4.1.	License Fees. In consideration of the licenses granted and the PER.C6® KNOW HOW supplied hereunder, LICENSEE shall pay the following amounts to CRUCELL
during the TERM: 

  

	 	4.1.1.	Within ten (10) days from the EFFECTIVE DATE, a License Issuance Fee of € 75,000 (seventy-five thousand Euros), exclusive of V.A.T.; and 

 

	 	4.1.2.	Starting on the first anniversary date of the EFFECTIVE DATE (TBD when the first anniversary date should start, since we are already paying an annual fee with a different anniversary date), an Annual License Maintenance
Fee of € 100,000 (one hundred thousand Euros), exclusive of V.A.T., to be paid in arrears. 

  
 10 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

	 	4.2.	Development Milestone Payments: LICENSEE shall pay CRUCELL non-creditable and non-refundable payments of € 400,000 (four hundred thousand Euros), exclusive of V.A.T., with respect to each PRODUCT for which a
governmental health regulatory authority grants marketing approval, within thirty (30) days of the issuance of the first regulatory marketing approval letter from such governmental health regulatory authority for the first indication for each
such PRODUCT. Payment under this Section 4.2 shall be made once for each unique PRODUCT. 

  

	 	4.3.	Running Royalty. LICENSEE shall pay to CRUCELL a running royalty (the “Running Royalty”) as follows: 

  

	 	4.3.1.	If PACKAGING CELLS and/or PACKAGING CELL KNOW-HOW are, or were, used in the development, use, manufacture, importation or sale of the PRODUCT, a Running Royalty of one and half a percent (1.5%) of the NET SALES for
the longer of (i) ten (10) years from the FIRST COMMERCIAL SALE of the PRODUCT; 

  

	 	4.3.2.	If the use, manufacture, importation or sale of the PRODUCT comes under the scope of at least one VALID PATENT CLAIM, on a country by country basis, a Running Royalty of half a percent (0.5%) of NET SALES.

  

	 	4.3.3.	Only one Running Royalty, that may be either a Know-How Royalty (Section 4.3.1), or a Patent Royalty (Section 4.3.2) or a combination of the Know-How and Patent Royalties (1.5 + 0.5 = 2.0%), shall be due with respect to
the same unit of PRODUCT. 

  

	5.	PAYMENTS; BOOKS AND RECORDS 

  

	 	5.1.	Royalty Reports and Payments. After the FIRST COMMERCIAL SALE of the PRODUCT on which Running Royalties are required, LICENSEE shall submit quarterly written reports to CRUCELL within ninety (90) days after
the end of each calendar quarter, stating in each such report the number, description, and aggregate NET SALES of the PRODUCT sold during the calendar quarter upon which a Running Royalty is payable under Section 4 above. Concurrently with the
submission of such reports, LICENSEE shall pay to CRUCELL Running Royalties at the rate specified in Section 4. 

  

	 	5.2.	LICENSEE Obligations. LICENSEE shall be solely responsible for the payment to CRUCELL of any royalties, license fees and milestone or other payments due from its AFFILIATES and/or SUBLICENSEES, and for any
payments to third parties under licenses or similar agreements between LICENSEE and such third parties necessary to allow the manufacture, use or sale of the PRODUCT by LICENSEE, or SUBLICENSEES; 

 

	 	5.3.	Method of Payment. 

  

	 	5.3.1.	All payments due hereunder to CRUCELL shall be paid in Euros in immediately available funds, for CRUCELL’s account, to a bank designated in writing by CRUCELL. CRUCELL shall provide LICENSEE with an invoice
prior to the due dates specified in Section 4.1.2 and 4.2, and LICENSEE shall pay such invoices within the later of the applicable due date or thirty (30) days of receipt by LICENSEE. If the invoice is received later than the due date,
then LICENSEE shall have thirty (30) days from the receipt of the invoice to pay the invoiced amount. 

  

	 	5.3.2.	CRUCELL shall submit an invoice to LICENSEE for all transportation, packing or other documented and reasonable costs incurred on LICENSEE’S benefit and at LICENSEE’S request pursuant to this Agreement in
connection with providing PACKAGING CELL KNOW HOW to LICENSEE. LICENSEE shall pay invoices specifying these reasonable costs within thirty (30) days of receipt. 

  
 11 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

	 	5.3.3.	Inflation Index Adjustment: Commencing from the first (1st) anniversary date of the EFFECTIVE DATE, license fees due under Setion 4.1 shall be increased by two and one half percent (2.5%) upon each anniversary
of the EFFFECTIVE DATE until and including the eighth anniversary of the EFFECTIVE DATE. 

  

	 	5.4.	Interest. If LICENSEE fails to make any payment under this Agreement within ninety (90) days of the date on which the same becomes due and payable, LICENSEE shall owe CRUCELL interest at the rate of twelve
and a half percent (12.5%) per annum (as determined on the date the payment first become due) on any outstanding amount until payment is made in full. If parties are in dispute on the amount of the royalties payable pursuant to Clause 5.1. the
penalty becomes due only after Parties have agreed on the exact royalty amount due. 

  

	 	5.5.	No Refunds. Payments referred to in this Section 5 shall not be refundable under any circumstances, including but not limited to the termination of this Agreement for whatever reason. 

 

	 	5.6.	Currency Conversion. If any currency conversion shall be required in connection with the calculation of royalties hereunder, such conversion shall be made using the following procedures. Sales recorded during a
month will be translated to Euro values at the rate on the 1st working day of that month based on the exchange rates published on the OANDA website. Any changes to procedures for currency conversion shall only apply after such notice has been
delivered and provided that such changes are consistently applied across LICENSEE’s operating units and continue to maintain a set methodology for currency conversion. 

 

	 	5.7.	Withholding Taxes. If LICENSEE is required by any applicable law, rule or regulation to make any deduction or withholding for or on account of any Tax (as defined below) from any payment to be made to CRUCELL
under this Agreement, then LICENSEE shall (i) promptly notify CRUCELL of such requirement, (ii) pay to the relevant authorities the full amount required to be deducted or withheld promptly upon determining that such deduction or
withholding is required or receiving notice that such amount has been assessed against CRUCELL, and (iii) promptly forward to CRUCELL an official receipt, or certified copy or other documentation reasonably acceptable to CRUCELL, evidencing
such payment to such authorities. 

  

	 	5.7.1.	If CRUCELL is entitled to an exemption from or reduction of withholding tax under any applicable law or treaty with respect to any payments made hereunder, CRUCELL shall deliver to LICENSEE at the time or times
prescribed by applicable law or reasonably requested by LICENSEE, such properly completed and executed documentation prescribed by applicable law as will permit such payments to be made without withholding or at a reduced rate. 

 

	 	5.7.2.	For purposes of this Section, the term “Tax” shall mean any present or future tax, levy, impost, duty, charge, assessment or fee of any nature (including interest, penalties and additions thereto) that is
imposed by any government or other taxing authority in respect of a payment under this Commercialization Agreement. 

  
 12 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

	 	5.8.	Records; Inspection. LICENSEE shall and shall cause its REGISTERED AFFILIATES and its SUBLICENSEES shall keep complete, true and accurate books of account and records for the purpose of determining the Running
Royalty amounts payable under this Agreement. Such books and records shall be kept at the principal place of business of LICENSEE, and SUBLICENSEES, as the case may be, for at least three (3) years following the end of the calendar quarter to
which they pertain. Such records will be open for inspection during such three (3) year period by an independent public accounting firm of national prominence retained by CRUCELL and acceptable to LICENSEE for the purpose of verifying the
Running Royalty statements. Such inspections may be made no more than once each calendar year, at reasonable times mutually agreed to by LICENSEE and CRUCELL. CRUCELL’s representative or agent will be obliged to execute a reasonable
confidentiality agreement prior to commencing any such inspection. Inspections conducted under this Section shall be at CRUCELL’s expense, unless a variation or error producing an increase exceeding ten percent (10%) of the Running Royalty
amount stated for any period covered by the inspection is established in the course of any such inspection, whereupon all reasonable and customary costs relating to the inspection for such period will be paid by LICENSEE. 

 

	6.	TERM AND TERMINATION 

  

	 	6.1.	Agreement Term. This Agreement shall become effective as of the EFFECTIVE DATE and, unless earlier terminated pursuant to the other provisions of this Section, shall continue in full force and effect on a
country-by-country basis, until LICENSEE has no remaining obligation to pay to CRUCELL the Running Royalty in accordance with Section 4.3. Thereafter, LICENSEE shall have a fully paid up, world wide, royalty free, perpetual license right under
the PER.C6® PATENTS and PER.C6® KNOW HOW to continue to make, have made, import, use, offer for sale and sell the
PRODUCT(S) in such countries. 

  

	 	6.2.	Termination by LICENSEE. LICENSEE may terminate this Agreement by giving CRUCELL three (3) months prior written notice, and payment of all outstanding monies owed to CRUCELL until the date of termination,
such as partial payment of arrears obligations pursuant to Section 4.1.2, which payment is due prior to actual termination of the Agreement. 

  

	 	6.3.	Termination by Mutual Agreement. This Agreement may be terminated upon mutual written agreement between the Parties. 

  

	 	6.4.	Termination Upon Insolvency or Bankruptcy. Either Party may terminate this Agreement, by notice to the other Party with immediate effect, if (a) the other Party (i) pledges substantially all of its
assets for the benefit of creditors, and the conditions for the creditors to enforce their rights to control those assets have been satisfied (such as the expiration of a cure period for an uncured default), institutes, consents to or fails to
diligently oppose any proceeding seeking to adjudicate it a bankrupt or insolvent or (b) any proceeding is instituted against or in respect of the other Party by third parties seeking bankruptcy relief and such proceeding continues undismissed,
or unstayed and in effect for a period of 60 days after the institution thereof. 

  

	 	6.5.	 Termination by Default. If either Party defaults in the performance of, or fails to be in compliance with, any material condition or covenant
of this Agreement and any such default or noncompliance shall not have been remedied, or steps initiated to remedy the same, to the other Party’s reasonable satisfaction within three (3) months for payment defaults, and within six
(6) months for other defaults or non-compliance, after receipt by the defaulting Party of a written notice thereof from the other Party, the Party not in default may, without further notice, forthwith terminate this Agreement at its option,
provided however that in the event of breach by CRUCELL, accrual and payment 

  
 13 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

	 	
of any amounts due to it hereunder shall be suspended during the cure period; and provided, further, that in the event of a dispute as to default, non-compliance or right to terminate this
Agreement, this Agreement shall continue until such dispute is finally resolved pursuant to Section 10.3 hereof. 

  

	 	6.6.	Rights and Obligations on Term, Termination, or Suspension. 

  

	 	6.6.1.	Unless expressly provided to the contrary, the following provisions shall survive the termination of this Agreement: Sections 1, 2.3, 2.5, 3.5.4, 3.5.5, 6.6, 6.7, 7, 8, 9 and 10 hereof. 

 

	 	6.6.2.	Return of PACKAGING CELL KNOW HOW. Except in the case of termination by LICENSEE for default pursuant to Section 6.5, upon early termination of this Agreement by either Party, at CRUCELL’S written
request, LICENSEE and its AFFILIATES shall destroy all supplies of PACKAGING CELL KNOW HOW, and shall promptly thereafter confirm such destruction in writing to CRUCELL, except for one copy of such written information to be retained in confidential
files and to be used solely to establish rights and obligations under this Agreement, and for no other use or purpose. 

  

	 	6.7.	Termination by either Party pursuant to this Article shall not prejudice any other remedy that a Party might have at law or equity. 

 

	7.	CONFIDENTIALITY 

  

	 	7.1.	Confidentiality Obligations. Each Party shall maintain in confidence all information disclosed or otherwise made available by the other which is identified as confidential and which is confirmed in writing and
marked “confidential” or otherwise properly labeled as confidential within thirty (30) days of such original disclosure, including without limitations, information relating to PACKAGING CELL KNOW HOW and PROGRAMS or results of
PROGRAMS (all such information hereafter referred to as “INFORMATION”), and shall not use such INFORMATION or disclose the same to anyone, except (i) that LICENSEE may disclose CRUCELL’S INFORMATION to its REGISTERED AFFILIATES
and SUBLICENSEES, those of its agents, direct employees, consultants and investigators for the execution of PROGRAMS and manufacturing and sale of PRODUCTS, as set out in this Agreement; (ii) that LICENSEE may disclose CRUCELL’S
INFORMATION as required to governmental health regulatory authorities; (iii) that CRUCELL may disclose LICENSEE’S INFORMATION to its agents, direct employees, consultants and investigators who have a need-to-know for the performance of
this Agreement; the foregoing as permitted by this Agreement and subject to the responsibilities and obligations as set forth in this Agreement. Either Party may disclose the other Party’s INFORMATION to potential investors and/or strategic
partners within the course of a good faith due diligence inquiry to the extent relevant for the purpose of the inquiry. The foregoing is subject to the below: 

  

	 	7.1.1.	Prior to such permitted disclosure to such LICENSEE REGISTERED AFFILIATES and SUBLICENSEES, Contractors, agents, direct employees, consultants, investigators, potential investors and other financing sources, investment
bankers, advisors, attorneys, accountants and strategic investors, disclosure must be subject to the provisions of a confidentiality agreement containing restrictions no less stringent than the obligations in this Section 7.1 as such
restrictions apply to LICENSEE, provided that attorneys and accountants shall not be required to execute such agreement if so informed of the confidential obligations hereunder and provided their professional code of conduct requires that such
confidentiality obligations be so observed. 

  
 14 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

	 	7.1.2.	Each Party shall use a similar effort to that which it uses to protect its own trade secrets or proprietary information (but that in any event be no less than customary industry standards) to protect the other
Party’s INFORMATION and to ensure that its applicable AFFILIATES and SUBLICENSEES and Contractors (if any), agents, direct employees, consultants, investigators, potential investors and strategic investors do not disclose or make any
unauthorized use of such INFORMATION. Each Party shall notify the other promptly of its knowledge of any unauthorized use or disclosure of the other’s INFORMATION and enable it to enforce rights against such use or disclosure.

  

	 	7.2.	Exceptions. The confidentiality and non-use obligations under this Agreement shall not apply to the extent that: 

  

	 	7.2.1.	the Party who has received the INFORMATION (“RECIPIENT”) is required to disclose information by order or regulation of a governmental agency or court of competent jurisdiction subject to the provisions of
Section 7.3.3 below; or 

  

	 	7.2.2.	the RECIPIENT can demonstrate that 

  

	 	7.2.2.1.	the party who has received the INFORMATION (“RECIPIENT”) is requited to disclose information by order or regulation of a governmental agency to court of competent jurisdiction subject to the provisions of
Section 7.3.3 below or; 

  

	 	7.2.2.2.	the disclosed INFORMATION is independently developed without use or regard to the INFORMATION (as shown by RECIPIENT’s written records); or 

 

	 	7.2.2.3.	the disclosed INFORMATION was lawfully known by RECIPIENT (as shown by its written records) prior to the date of disclosure to RECIPIENT without an obligation of secrecy, from sources legally entitled to disclose the
same without an obligation of secrecy or received by RECIPIENT (as shown by its written records) on an unrestricted basis from a source unrelated to any Party to this Agreement and not, to its knowledge, under a duty of confidentiality.

  

	 	7.3.	Publications and Public Announcements: 

  

	 	7.3.1.	Each party shall have the right to publish the existence of this Agreement, but not the terms thereof, with the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed.

  

	 	7.3.2.	Any disclosure which is required by law may be made without the prior consent of the other Party, although the other Party shall be given prompt notice of any such legally required disclosure and an opportunity to
comment on, and attempt to challenge or limit the proposed disclosure reasonably in advance to the extent feasible. 

  

	 	7.3.3.	Furthermore, the disclosing Party shall make diligent efforts to limit the nature and scope of any disclosure to the extent reasonably possible and to otherwise prevent the disclosure of the non-disclosing Party’s
INFORMATION. 

  
 15 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

	8.	PATENTS 

  

	 	8.1.	CRUCELL shall be responsible and use commercially reasonable efforts for the prosecution, protection and maintenance of PER.C6® PATENTS throughout the TERM, and
shall bear all costs, fees and expenses in connection thereto. 

  

	 	8.2.	If either Party after the EFFECTIVE DATE is warned or sued by a third party alleging or charging infringement of any patents or published patent applications or any other rights, due to or in connection with the use of
PACKAGING CELLS, by either Party, the Party which is warned or sued, shall notify promptly the other Party. 

  

	 	8.3.	CRUCELL shall be responsible, at its expense, for settling and/or defending any warning or litigation for patent infringement in which the alleged infringing process or product giving rise to liability for damages
involves or arises from use by CRUCELL of PACKAGING CELLS or the practice of any of the PACKAGING CELLS, PER.C6® PATENTS or PACKAGING CELL KNOW-HOW. 

In so far as any such infringement action, or the settlement or defense thereof, might have an effect on LICENSEE activities, CRUCELL shall
promptly inform LICENSEE of such claim and (i) CRUCELL and LICENSEE shall confer as to any modification of any right granted to LICENSEE hereunder, provided, that such modification shall not substantially alter LICENSEE’s rights hereunder;
(ii) LICENSEE shall be entitiled, but shall not be obligated, to attempt to obtain a license from such third party for the right to use such third party’s patent or other applicable right and (iii) in the event that LICENSEE is named
thereunder, it shall have the right to participate in the defense of such claim. In any event, if such infringement action might have an effect on LICENSEE activities (i) upon CRUCELL’s written request, LICENSEE agrees to reasonably assist
CRUCELL in any such defense; and (ii) LICENSEE shall be entitled to immediately terminate this Agreement. 
 If LICENSEE should suffer
any out of pocket costs and other expenses, including reasonable attorney’s fees, as a result of the assistance in such dispute, CRUCELL shall reimburse LICENSEE such out of pocket costs and expenses incurred by LICENSEE. 

LICENSEE shall be responsible, at its expense, for settling and/or defending any warning or litigation for patent infringement made against
CRUCELL, in which the alleged infringing process or product giving rise to liability for damages involves use by LICENSEE of PACKAGING CELLS, other than as set forth in Section 8.3 above. If CRUCELL should suffer any damages, losses, out of
pocket costs and other expenses and liabilities as a result of such dispute, including reasonable attorney’s fees and payments of royalties to third parties, LICENSEE shall indemnify CRUCELL and it AFFILIATES and hold them harmless against any
such expenses and liabilities. 
  

	 	8.4.	No Party shall enter into any settlement which admits or concedes that any aspect of the PATENT or know how of the other Party is invalid or unenforceable in any way, without the prior written consent of such other
Party. 

  

	9.	REPRESENTATIONS; WARRANTY, INDEMNIFICATION 

  

	 	9.1.	 CRUCELL Representations and Warranties. CRUCELL represents and warrants that (a) CRUCELL has the full legal right to enter in this
Agreement and to perform its obligations thereunder; (b) CRUCELL will not be violating any law, regulation, order or contractual or other obligations of or applicable to CRUCELL or to the
PER.C6® CELLS, PER.C6® PATENTS or PER.C6® KNOW-HOW by executing, delivering or
performing this Agreement, and neither the execution or delivery of this Agreement shall not conflict with or violate any 

  
 16 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

	 	
such law, regulation, order or contractual or other obligation; (c) CRUCELL has duly executed and delivered this Agreement, which constitutes a legal valid and binding obligation of CRUCELL,
enforceable against CRUCELL in accordance with its terms; (d) CRUCELL is the legal owner of all rights and title in and to the PER.C6® CELLS, PER.C6® PATENTS and PER.C6® KNOW HOW licensed hereunder, free and clear of any encumbrance, charge or restriction, and has the right to grant
LICENSEE the licenses granted under this Agreement without conflicting with any third party rights and without creating any encumbrance, charge or restriction in connection therewith; (e) the
PER.C6® CELLS provided to LICENSEE or to a designated contractor under 2.1.4 (i) comply with the certificates of analysis that accompany the cells, (ii) comply with the
specifications as set forth in the Exhibits hereto, and (iii) have been manufactured, tested and maintained according to the current ICH, FDA and EMEA guidelines; (f) the terms of this Agreement do not create a conflict with or result in
the breach of any right, obligation or agreement that CRUCELL has with any third party; (g) it has not received any communication alleging that the PER.C6® CELLS infringes the
intellectual property rights of any third party; and (h) CRUCELL will prosecute, maintain and take other actions necessary, in the course of its exercise of good business judgment, to support the continued validity and enforceability of the
PER.C6® PATENTS during the term. UNLESS OTHERWISE EXPRESSLY PROVIDED FOR IN THIS AGREEMENT, CRUCELL DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES
OF MERCHANTABILITY, NON-INFRINGEMENT, FITNESS FOR ANY PARTICULAR PURPOSE, RESPECTING ANY MATERIALS PROVIDED TO LICENSEE PURSUANT TO, OR IN ASSOCIATION WITH THE PERFORMANCE OF THIS AGREEMENT, INCLUDING ANY WARRANTIES CONCERNING THE INHERENT
PROPERTIES OF PACKAGING CELLS SUPPLIED UNDER THIS AGREEMENT. CRUCELL MAKES NO WARRANTY AS TO THE MERCHANTABILITY OF THE PRODUCTS, PER.C6® KNOW HOW OR PER.C6® PATENTS. 

  

	 	9.2.	LICENSEE Warranties. LICENSEE (a) is entitled to enter in this Agreement and to perform its obligations thereunder; (b) LICENSEE does not violate any law, regulation, order or its existing contractual
obligations by executing, delivering and performing this Agreement; and (c) LICENSEE has duly executed this Agreement, which constitutes a legal valid and binding obligation of LICENSEE, enforceable against LICENSEE in accordance with its
terms. 

  

	 	9.3.	Product Liability and Indemnification. CRUCELL shall not be liable for and LICENSEE shall indemnify CRUCELL and hold CRUCELL harmless against any and all liabilities (including product liability), damages, losses
or injury, death, costs and expenses, including reasonable attorney’s fees, arising in any manner from the use by LICENSEE or its AFFILIATES of PACKAGING CELLS and/or the PACKAGING CELL KNOW HOW, or the use of any PRODUCT by any human being,
regardless of whether such use was contemplated by the Parties, except to the extent such liabilities result from (i) the willful misconduct, gross negligence or written instructions of CRUCELL; and/or pursuant to Section 8.3 above; and/or
(iii) any breach of this Agreement by CRUCELL. CRUCELL shall hold harmless LICENSEE and its AFFILIATES against losses arising from the events set forth in clauses (i) and (ii) immediately above. 

 

	10.	MISCELLANEOUS/ RULES OF CONSTRUCTION 

  

	 	10.1.	 Amendment. This Agreement may not be changed, modified, amended, or supplemented except by a written instrument signed by authorized representatives of both Parties hereto. 

  
 17 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

	 	10.2.	Assignability. LICENSEE’s rights and obligations in this Agreement may not be assigned without the prior written consent of CRUCELL, except to an AFFILIATE, or in the event of a merger or sale of all, or
substantially all, of LICENSEE’s assets relating to the subject matter of this Agreement to an assignee, provided that LICENSEE shall remain joint and severally liable with any such assignee for the performance of its assigned
obligations hereunder if LICENSEE continues to conduct business following such merger or sale. Such assignment shall then be binding upon, inure to the benefit of the Parties, and be enforceable. Any attempted assignment contrary to the terms of
this provision shall be void. 

  

	 	10.3.	Choice of Law and Dispute Resolution. This Agreement shall be governed by and construed under the laws of the Netherlands. If any dispute arises out of this Agreement, the Parties will themselves endeavor to
settle such dispute amicably. If the Parties fail to arbitration before a single arbitrator, such arbitration to be held in accordance with the rules of arbitration of the International Chamber of Commerce and to be held in The Hague, Netherlands.
The Parties shall use good faith efforts to expedite the arbitration. The parties agree that any judgment of the foregoing arbitrator shall be final and binding and shall be enforceable in any competent court having jurisdiction over the adjudged
party. Nothing herein shall prevent either party from seeking injunctive relief or other equitable remedies in or out of law. 

  

	 	10.4.	Expenses. Each Party shall bear its own expenses, if not expressly agreed otherwise in this Agreement. 

  

	 	10.5.	Force Majeure. Neither LICENSEE nor CRUCELL shall be liable for any failure or delay in performance under this Agreement which is due in whole or in part directly or indirectly to any cause of any nature beyond
the reasonable control of such Party. 

  

	 	10.6.	Further Assurances. Each Party hereto agrees to execute, acknowledge and/or deliver such further instruments, and to do all other acts, as may be necessary or appropriate in order to carry out the purposes and
intent of this Agreement. 

  

	 	10.7.	Notice and Reports. All notices required by this Agreement shall be in writing. All notices and reports shall be sent by fax followed by registered airmail to the Parties at the following addresses or such other
addresses as may be designated in writing by the respective Parties: 

  

			
	 To CRUCELL:
	  	 CRUCELL HOLLAND B.V.
 Archimedesweg 4

P.O. Box 2048
 2301 CA Leiden

THE NETHERLANDS
 Attn. Business Development

FAX: +31-71-5248702
  

	 To LICENSEE:
	  	 VASCULAR BIOGENICS Ltd.
 6 Jonathan Netanyahu
Street,
 60376, Or-Yehuda,
 ISRAEL

Attn. Emmanuel Elalouf
 VP Business Development

FAX: 972-3-6346449

 Any notices shall be deemed given when received by the other Party. 

  
 18 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

	 	10.8.	Relationships of the Parties. Both Parties are independent contractors under this Agreement. Nothing contained in this Agreement is intended nor is to be construed so as to constitute CRUCELL and LICENSEE as
agents, partners or joint ventures with respect to this Agreement. Neither Party hereto shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other
Party to any other contract, agreement, or undertaking with any third party. 

  

	 	10.9.	Rules Of Construction. 

  

	 	10.9.1.	Captions. Paragraph captions are inserted for convenience only and in no way are to be construed to define, limit or affect the construction or interpretation hereof. 

 

	 	10.9.2.	Entire Agreement. This Agreement contains the entire agreement of the Parties regarding the subject matter hereof, and supersedes all prior agreements, understandings, and negotiations between the Parties
regarding the same. 

  

	 	10.9.3.	“Including”. The words “include”, “including” or “included” are used to indicate that the matters listed are not a complete enumeration of all matters covered and should be
read such as “including but not limited to”. 

  

	 	10.9.4.	Singular, Plural, Gender. Words denoting the singular, shall include the plural and vice versa. Words denoting one gender shall include all others. 

 

	 	10.9.5.	Severability. If any part of this Agreement shall be held invalid and/or unenforceable, the remaining provisions of this Agreement shall nevertheless remain in full force and effect provided that such provisions
will permit the transaction contemplated herein to take place in substantially the same manner as originally contemplated by the Parties. 

  

	 	10.9.6.	Translations. This Agreement has been written and executed in the English language. Any translation into any other language shall not be an official version of this Agreement. In the event of any conflict in
interpretation between the English version and such translation of this Agreement, the English version shall prevail. 

  

	 	10.9.7.	Waiver. The waiver by either Party of a breach of any provisions contained herein shall be in writing and shall in no way be construed as a waiver of any prior or succeeding breach of such provision or the waiver
of the provision itself. 

  

	 	10.9.8.	Trademarks. PER.C6® is a registered trademark of CRUCELL. All right title and interest therein shall remain with CRUCELL. CRUCELL is solely entitled to all
goodwill accruing in the trademark PER.C6® as a consequence of the use thereof by LICENSEE or otherwise. LICENSEE may only use CRUCELL’s
PER.C6® trademark upon the execution of a separate trademark license agreement with CRUCELL. Not withstanding the aforementioned, for the avoidance of doubt LICENSEE can use the PER.C6® trademark for reference purposes in connection with research publications as well as regulatory filings. 

  

	 	10.9.9.	Use of Party’s Name. No right, express or implied, is granted by tHIS AGREement to LICENSEE to use in any manner other than for regulatory submission purposes the name “CRUCELL” or
“INTROGENE”, or to CRUCELL to use in any manner the name of LICENSEE or its Affiliates, or any other trade name, logo or trademark of the other party in connection with the performance of this Agreement without prior permission from such
other party except as elsewhere permitted under this Agreement. 

  
 19 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

 IN WITNESS WHEREOF, the Parties hereto have executed this Agreement to be effective as of the date the
last Party signs below. 
  

									
	VASCULAR BIOGENICS LTD.	 		 	CRUCELL HOLLAND B.V.
		 		 	For and on behalf of Crucell N.V.
					
	By:	 	/s/ Dror Harats	 		 	By:	 	/s/ [Illegible]
		 		 		 		 	Crucell NV, represented by
				
	Or Yehuda, April 14, 2011	 		 		 	Leiden April 13, 2011

  
 20 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

 [***] 

  
 21 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

 Exhibit 1.2 – APPROVED COUNTRIES 

United States of America 
 Canada 

The member states of the European Union on the EFFECTIVE DATE 

Israel 
 Japan 

Australia 
 New Zealand 

  
 22 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

 [***] 

  
 23 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

 Exhibit 1.24 – REGISTERED AFFILIATES 

  
 24 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

 EXHIBIT 1.25 – FORM OF MATERIAL TRANSFER AGREEMENT FOR STRATEGIC PARTNER 

  
 25 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

 EXHIBIT 1.25 – FORM OF MATERIAL TRANSFER AGREEMENT FOR A CONTRACTOR 

  
 26 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

 Attachment I: Statement of Work to which the use of the MATERIAL is to be limited 

Contractor may only use MATERIAL and INFORMATION for 

  
 27 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

 EXHIBIT 2.4.2 – PRE-APPROVED THIRD PARTY CONTRACTORS 

  
 28 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

 Exhibit 3.5.1– Quarterly reporting form 

To: 
 CRUCELL HOLLAND B.V. 

Archimedesweg 4 
 P.O.Box 2048 

2301 CA Leiden 
 THE NETHERLANDS 

Attn. Business Development 
 FAX: +31-71-5248702 

From: (Please fill in COMPANY name and address) 

 
  

 
 Date:
                     
 Subject: QUARTERLY
REPORT LICENSE AGREEMENT 
  

	 	1)	Period covered by the report 

					
		  	 	  	

  

	 	2)	General culturing 

  

	 	•	 	A short description on general cell culture activities. 

  

	 	•	 	Have you encountered problems culturing the PER.C6® cell line? 

  

	 	•	 	Have you seen substantial deviations from the culture protocols described in the PER.C6® KNOW HOW FILE? 

 

					
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	

  
 29 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

	 	3)	VECTOR production 

  

	 	•	 	Number and types of Protein/MAB produced in the PER.C6® cell line. 

  

	 	•	 	Have you encountered problems or observed remarkable results when transfecting the PER.C6® cell line, or when creating MODIFIED CELLS? 

 

	 	•	 	Any substantial deviations from and/or additions to the protocols provided in the PER.C6® KNOW HOW FILE? 

 

	 	•	 	Code(s) for tracking the individual Protein/MAB in future reports. 

  

					
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	

  

	 	4)	Interactions with regulatory authorities 

  

	 	•	 	In the past three months, were there any communications with regulatory authorities that were NOT subject to Section 3.4.3 of the License Agreement? If YES, please provide a summary of the reason, the nature and
the outcome of these discussions. Please provide copies of the communication. 

  

	 	•	 	What safety, tumorgenicity and/or other tests have been performed on the PACKAGING CELLS for regulatory purposes? Please provide reason, nature and outcome of the tests. 

 

					
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	

  
 30 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

 Exhibit 3.5.2. – Annual reporting form 

To: 
 CRUCELL HOLLAND B.V. 

Archimedesweg 4 
 P.O.Box 2048 

2301 CA Leiden 
 THE NETHERLANDS 

Attn. Business Development 
 FAX: +31-71-5248702 

From: (Please fill in COMPANY name and address) 
  

 
  

 
 Date:
                     
 Subject: ANNUAL REPORT
LICENSE AGREEMENT 
  

	 	1)	Period covered by the report 

											
		  	 	  		  		  		  	

  

	 	2)	General culturing 

  

	 	•	 	A short description on general cell culture activities. 

  

	 	•	 	Media used. 

  

	 	•	 	Cell banks prepared. 

  

	 	•	 	General performance; cell growth, viabilities, doubling times. 

  

	 	•	 	Scale and scale-up data. 

  

	 	•	 	Systems used (Shake-flasks, Roller bottles, Bioreactors, Wave bags). 

  

	 	•	 	Have you encountered problems culturing the PER.C6® cell line? 

  

	 	•	 	Have you seen substantial deviations from the culture protocols described in the PER.C6® KNOW HOW files? 

 

					
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	

  
 31 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

	 	3)	VECTOR production 

  

	 	•	 	Number and type of vectors produced in the PER.C6® cell line. 

  

	 	•	 	Yields reached per produced VECTOR. 

  

	 	•	 	Have you encountered problems or observed remarkable results when transfecting the PER.C6® cell line, or when creating MODIFIED CELLS? 

 

	 	•	 	Any substantial deviations from and/or additions to the protocols provided in the PER.C6® KNOW HOW FILE? 

 

	 	•	 	Code(s) for tracking the individual new PRODUCT in future reports. 

  

					
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	

  

	 	4)	Third party activities 

  

	 	•	 	Have you performed CMO activities for third parties using the PER.C6® cell line or worked with the
PER.C6® cell line in collaborations programs with third parties? If yes, please state the name of the company/companies and a short description of the project(s). 

 

	 	•	 	Has a CMO performed any activities with the PER.C6® cell line? If yes, please state the name of the company/companies and a short description of the project(s).

  

					
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	

  
 32 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***]. 

 Commercial License Agreement PER.C6® 

Crucell Holland – Vascular Biogenics 
  

	 	5)	Interactions with regulatory authorities / Clinical activities 

  

	 	•	 	What pre-IND meetings and IND filings have taken place for products produced on PER.C6®? For which products? What was the outcome (related to PER.C6®) of those meetings? 

  

	 	•	 	Were there any communications with regulatory authorities that were NOT subject to Section 3.4.3 of the License Agreement? If YES, please provide a summary of the reason, the nature and the outcome of these
discussions. Please provide copies of the communication. 

  

	 	•	 	What safety, tumorgenicity and/or other tests have been performed on the PACKAGING CELLS for regulatory purposes. Please provide reason, nature and outcome of the tests. 

 

	 	•	 	Was clinical material produced using the PER.C6® cell line? 

  

					
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	
		  	 	  	

  
 33 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by
[***].EX-10.4

 Exhibit 10.4 

AGREEMENT 
 This Agreement
(“Agreement”) is made and entered into as of the 3 day of February 2013 (“Effective Date”), by and between: 
 Tel
Hashomer - Medical Research, Infrastructure and Services Ltd., a private company duly incorporated under the laws of the State of Israel having its registered office at Tel Hashomer, Israel, 52621, represented by its authorized representatives
(“THM”); and 
 Prof. Dror Harats, ID no. 054496641 of Ramat Gan, Israel (“Prof. Harats”); and

 Vascular Biogenics Ltd., Company no. 51-289976-6, a private company duly incorporated under the laws of the State of Israel having its
registered office at 6 Yoni Netanyahu Street, Or Yehuda, Israel, 60376, represented by its authorized representatives (“VBL” or the “Company”). 

 

	WHEREAS:	THM declares that it is a private company, whose purpose is to promote the welfare of the Sheba Medical Center (the “Hospital”); and 

 

	WHEREAS:	THM declares that at the request of the Hospital and the Fund, as defined below, THM undertook to act as the operational body of the Hospital and Fund, with respect to promotion, development and commercialization
of intellectual property deriving from inventions of Hospital’s and/or Fund’s employees;and 

  

	WHEREAS:	Prof. Harats has been an employee of the Hospital and/or the Fund since 1995; and 

  

	WHEREAS:	VBL was established in 1999; and 

  

	WHEREAS:	The Hospital and the Fund have claims regarding the ownership of certain inventions and patent rights of the Company, developed in part by Prof. Harats, and certain other inventors defined herein as Inventors and VBL
disagrees, denies and refutes all such claims in their entirety; and 

  

	WHEREAS:	THM, on behalf of the Hospital, and the Fund reached an agreement resolving the above dispute as stipulated and set forth hereunder; 

  
  

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

 NOW, THEREFORE, in consideration of the mutual covenants and undertakings herein contained, the parties
hereby agree and stipulate as follows: 
  

	1.	PREAMBLE AND DEFINITIONS 

  

	 	1.1	The Preamble to this Agreement as well as all the Agreement’s appendices constitutes an integral part thereof. 

  

	 	1.2	The descriptive headings of this Agreement are inserted for convenience only and shall not be considered a part or affect the interpretation of this Agreement. 

 

	 	1.3	In addition to terms defined elsewhere in this Agreement or its appendices, the following terms shall have the meaning ascribed to them hereinafter: 

 

	 	1.3.1	“Affiliate” shall mean, with respect to a Party, any person, organization or entity controlling, controlled by or under common control with, such party. For purposes of this definition only,
“control” of another person, organization or entity shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the activities, management or policies of such person, organization or entity, whether
through the ownership of voting securities, by contract or otherwise. Without limiting the foregoing, “control” shall be presumed to exist when a person, organization or entity (i) owns or directly controls fifty percent (50%) or
more of the outstanding share capital or other ownership interest of the other organization or entity, or (ii) possesses, directly or indirectly, the power to elect or appoint fifty percent (50%) or more of the members of the governing
body of the organization or other entity. 

  

	 	1.3.2	The “Fund” shall mean Medical Research Infrastructure Development and Health Services Fund by the Sheba Medical Center (RA). 

 

	 	1.3.3	“Intellectual Property” shall mean any or all intellectual property and similar proprietary rights in any jurisdiction throughout the world, including without limitation: (i) all United States,
Israeli, international and foreign patents and applications therefor (including PCT), including any and all reissues, divisionals, patent of division applications, renewals, extensions, continuations, and continuity applications thereof, whether or
not related to such divisionals, patent of division application, renewals, extensions, continuations or continuity applications through one or more intervening applications, and any patent or application acquired as a result of prevailing in any
interference proceeding (the “Patent Rights”); (ii) all inventions (whether patentable or not), invention disclosures, trade secrets, proprietary information, know-how, technology, technical data and customer lists, and all
documentation in any form or media relating to any of the foregoing; (iii) all copyrights, copyrights registrations and applications therefor, and all other rights corresponding thereto throughout the world; (iv) all databases and data
collections and all rights therein throughout the world; (v) all trade names, logos, common law trademarks and service marks, trademark and service mark registrations and applications therefore throughout the world; and (vi) all domain
names, uniform resource locators, and other names and locators associated with the internet. 

  
 2 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

	 	1.3.4	The “Inventors” – As specifically detailed in Appendix A attached hereto and constituting an integral part thereof. Such Inventors are inventors who have been employed by Sheba.

  

	 	1.3.5	The “Company’s IP”: shall mean (i) the Intellectual Property owned, registered or controlled by the Company which is specified in Appendix B attached hereto; (ii)any
continuations in part of the Company’s IP listed in Appendix B; and (iii) any Intellectual Property to the extent that it is dated prior to the date hereof and incorporates and /or based upon the patents specified in
Appendix B and/or any Intellectual Property to the extent that it is dated prior to the date hereof and that the patents listed in Appendix B are based thereon. 

  

	 	1.3.6	The “Products” shall mean any product, agent, process, or service device which is covered by or is produced or manufactured or rendered (as the case may be) using a process or method covered by the
Company’s IP. 

  

	 	1.3.7	“Net Sales” shall mean the total amount invoiced by or on behalf of VBL or any of its Affiliates or Licensees, in connection with the sale of a Product after deduction of: (i) value added taxes,
excise and sales taxes, or other similar taxes imposed on such sales (excluding income or franchise taxes of any kind) (ii) amounts credited by a credit note; and (iii) reasonable quantities for promotional purposes, and compassionate
uses; provided however that the Company doesn’t receive any consideration relating thereto; 

  

	 	  	For the purpose hereof: (a) with respect to sales which are not at arm’s length and/or are not according to the current market conditions for such a sale, the term “Net Sales” shall mean the total
amount that would have been paid in an arm’s length sale made according to the current market conditions for such sale or according to market conditions for sale of products similar to the Products; (b) with respect to sales by VBL and/or
a Licensee, as applicable, to any Affiliate, the term, “Net Sales” shall mean the higher of: (i) “Net Sales”, as defined above in paragraph (a) and (ii) the total amount invoiced by such affiliated entity on resale
to an independent third party purchaser and (c) with respect to sales for non-monetary consideration for any Products, “Net Sales” shall be calculated based on the higher of: (i) “Net Sales”, as defined in paragraph
(a) above; and (ii) the total amount invoiced by the party acquiring the Products in such transaction in each case, after deducting the amounts permitted above, to the extent applicable. 

 

	 	1.3.8	“License” shall mean the grant of any right or license and any agreement executed, by VBL to or with any entity, permitting any use of Company’s IP (or any part thereof) including for the
development and/or manufacture and/or marketing and/or distribution and/or sale of Company’s IP, and/or the Products and the term “Licensee” shall be construed accordingly. 

  
 3 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

	 	1.3.9	“License Fee” shall mean the consideration of any type or nature, received (for the removal of doubt, whether received before or after the First Commercial Sale in any country) by the Company in return
for or in connection with the grant of Licences or the grant of an option for a Licence, and excluding amounts received by the Company which are included under the definition of “Net Sales” based on sales of the Products by Licensees, in
respect of which the Company has paid royalties to THM according to this Agreement or otherwise constitute payment upon Exit Event according to this Agreement; License Fee shall include any lump sums, revenues from License Fees, milestone payments,
etc. but shall specifically exclude reimbursement for research and development and patent related expenses/reimbursement for payments specifically committed to cover costs reasonably and actually incurred by Company under, and in accordance with
detailed budgets and workplans included in, license agreements with Licensees. Any consideration other than cash payment shall be calculated based on the fair market value of such consideration assuming an arm’s length transaction made in the
ordinary course of business. Upon request, the Company shall provide THM with all documents and figures reasonably necessary in order to verify Company’s compliance with this clause. 

 

	 	1.3.10	“First Commercial Sale” shall mean with respect to any Product in any country, the first commercial sale of the Product in such country after FDA Approval for marketing or equivalent approval in such
country has been obtained if such approval is required. 

  

	2.	PARTIES’ DECLARATIONS AND UNDERTAKINGS 

  

	 	2.1	THM undertakes and covenants as follows: 

  

	 	2.1.1	Subject to the performance of the Company’s obligations hereunder, THM hereby irrevocably confirms on behalf of the Hospital and the Fund that such entities, or anyone on their behalf do not have any further right
to receive any payment, compensation, funds or securities from Prof. Dror Harats and/or from the Company (including its officers, directors, shareholders, employees, affiliates, successors and assigns, whether current, past or in the future) and/or
the Inventors (the “Released Parties”) deriving from any claim of ownership in the Company’s IP, and hereby irrevocably waives and releases acquits and forever discharges each of the Released Parties from any and all rights,
claims, demands, commitments, actions, charges, complaints, promises, agreements, controversies, debts, counterclaims, suits, causes of action, damages, liabilities, obligations, costs and expenses of every kind and nature whatsoever, known or
unknown, past, present or future, at law or in equity, contingent or otherwise (collectively, a “Claim”), such parties, including their successors and/or assigns, may have, as a result of a claim of ownership in the Company’s
IP now or in the future, (“Released Matters”). 

  
 4 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

	 	    	Notwithstanding anything to the contrary in this Agreement, it is hereby clarified that the above waiver specified in this clause 2.1.1, applies and relates only to any part of the Company’s IP which is created,
conceived and/or developed by the Inventors and not to Company’s IP or any part thereof or any other Intellectual Property owned by the Company which is created, conceived and/or developed by any other inventors, employees, agents and/or
contractors on behalf of the Company to the extent they are not listed in Appendix A. 

  

	 	2.1.2	2.1.3 Prof Harats shall be entitled to serve as Chief Executive Officer and member of the Board of Directors of the Company to develop intellectual property that constitutes continuations in part of the Company IP and
subject to duly filing the required reports to THM and to the Ministry of Health, to receive compensation in shares and in cash, without any further claim by the Releasing Parties. 

 

	 	2.2	Each party hereby represents and warrants that: (a) it has the power and authority to execute and deliver this Agreement, and to perform its obligations hereunder, and that the execution, delivery and performance
by it of this Agreement and its compliance with the terms and provisions hereof do not and will not conflict with or result in a breach of any of the terms and provisions of or constitute a default under (i) any loan agreement, guaranty,
financing agreement, agreement affecting a product or other agreement or instrument binding or affecting it or its property; (ii) any other right or obligation provided under any other agreement or obligation that it has with any third party;
or (iii) any order, writ, injunction or decree of any court or governmental authority entered against it or by which any of its property is bound; (b) the Agreement is a binding enforceable obligation of such Party; and (c) no
consent, approval, authorization order, filing, registration, or qualification of or with any court, governmental authority, or third person is required to be made or obtained by a party in connection with the execution and delivery of this
Agreement or the consummation by a party of the transactions contemplated hereby, which has not been received. 

  
 5 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

	3.	LICENSE BY THE COMPANY 

 VBL undertakes that any License granted by it shall be subject to the
following terms: 
  

	 	3.1	The License is granted according to a written appropriate and binding agreement. The material terms of each License will be disclosed orally by the legal counsel of VBL to the head of THM prior to the execution of any
License agreement. Following execution of any such agreement, the Company will either (i) provide a copy of such agreement to THM; or (ii) if the provision of a copy of such agreement is not allowed under the terms thereof, disclose to
THM’s attorney and its accounting firm the material terms of such agreement, including without limitation, any terms that have bearing upon the consideration payable to THM hereunder. Such disclosure to THM’s attorney or CPA shall be
subject to their execution of a non disclosure agreement. The Company shall verify that the License includes terms that will allow the disclosure of the material terms thereof to THM or to a third party to be designated by THM, and shall comply with
such terms. 

  

	 	3.2	The License is being granted in a bona fide arms-length commercial transaction. 

  

	 	3.3	Non monetary consideration, if any, shall be valued as set forth in this Agreement. 

  

	4.	CONSIDERATION TO THM 

  

	 	4.1	VBL undertakes to pay THM the following amounts on a Product-by-Product and country-by-country basis until the later to occur of: (i) the last to expire or terminate of any of the Patent Rights covering such
Product in such country; or (ii) fifteen (15) years from the date of the First Commercial Sale of such Product in such country: 

  

	 	4.1.1	Royalties. VBL shall pay THM 1% (one percent) of Net Sales by or on behalf of VBL or any Affiliate or any Licensee (the “Royalties”). 

 

	 	4.1.2	Licensing Consideration. VBL shall pay THM 2% (two percent) of any License Fee received by VBL (the “Licensing Consideration”). 

 

	 	4.2	The amounts payable to THM under clause 4.1 shall be paid as follows: 

  

	 	4.2.1	Royalties, as specified in sub-clause 4.1.1 in connection with Net Sales by VBL and its Affiliate, shall be paid on a quarterly basis, within 60 (sixty) days after the end of each quarter in which the respective sale
took place, commencing on the first quarter where the First Commercial Sale took place. Royalties in connection with Net Sales by a Licensee shall be paid on a quarterly basis, within 60 (sixty) days after the end of each quarter in which VBL
receives payment on account of Net Sales. 

  

	 	4.2.2	Licensing Consideration, as specified in sub-clause 4.1.2 shall be paid within 30 (thirty) business days from receipt of any License Fee by the VBL. 

  
 6 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

	 	4.3	Consideration from Exit. Upon the closing of each Exit Event, as defined bellow, THM shall be entitled to receive from the Company 1% (one percent) of any and all consideration received by the Company and/or its
shareholders as a result of or in connection with such Exit Event (“Consideration From Exit”). 

 Consideration from Exit
Event under clause 4.3 shall be paid in cash within 15 (fifteen) days from the closing of the Exit Events defined above. To the extent that the applicable Exit Event is an IPO or the consideration is in kind and not cash payment then the Company may
pay the Consideration From Exit within 12 months following the closing of the respective Exit Event. 
 “Exit Event” means any of the
following events: (i) the closing of the merger or consolidation of VBL into or with other corporation or the acquisition of the Company thereby, excluding a transaction following which VBL is the surviving corporation and the shareholders of
VBL prior to the transaction constitute the majority of the shareholders following such transaction; or (ii) the closing of the sale of all or substantially all of the assets of VBL or all or substantially all of its issued and outstanding
share capital or (iii) the closing of an Initial Public Offering (“IPO”). Notwithstanding the above, in all cases, a transaction with a wholly owned subsidiary or a transaction effected for the purpose of changing the domicile
or structure of VBL shall not be deemed an Exit Event. 
  

	 	4.4.	Payment obligations under clause 4 shall expire if the payment to THM upon or prior to such Exit Event (but not by way of payment of Royalties under clause 4.1.1) is or exceeds NIS100 million. In addition, at any time
following the execution hereof the Company, its assignees or successors shall be entitled to terminate the payment obligations under clause 4 by payment to THM of the amount of NIS100 million after deduction of any amount previously received by THM,
provided that such amounts were not received by THM as Royalties under clause 4.1.1. It is hereby clarified that termination of the obligation to pay Consideration From Exit, according to this clause 4.4 which did not exceed NIS 100 million,
does not and shall not derogate from Company’s obligation for payments as specified in clauses 4.1.1 and 4.1.2 until an aggregate payment of NIS 100 million has been made (but not by way of payment of Royalties payable under clause 4.1.1).

  

	 	4.5	All amounts set forth herein are inclusive of any and all taxes. The Company (or the escrow agent, if applicable) shall be entitled to deduct at source or withhold from any amount payable hereunder any tax amount
applicable to THM in connection with each payment. 

  

	 	4.6	The Company shall report in writing to THM immediately upon execution of an agreement relating to the First Commercial Sale and upon the occurrence of such first Commercial Sale. The Company shall specify in such report
the date of execution of such agreement and the date of the First Commercial Sale according to the agreement. 

  

	 	4.7	In calculating Net Sales and License Fee, all amounts shall be expressed in US Dollars and any amount received or invoiced in a currency other than US Dollars shall be translated into US Dollars, for the
purposes of calculation, in accordance with the exchange rate between the US Dollar and such currency on the date of such receipt or invoice, as the case may be. 

  
 7 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

	 	4.8	The Company shall provide THM with the following written reports: (a) a detailed quarterly report, commencing with the first calendar quarter in which any Net Sales are made, or License Fee received, in a form
reasonably acceptable to THM, signed by the chief financial officer of VBL, specifying all amounts payable to THM under this clause 4 in respect of the previous quarter to which the report refers. Such report shall include: (i) the sales made
by the Company, Affiliates and Licensees with a breakdown of Net Sales according to country, identity of seller, currency of sales, dates of invoices, number and type of Products sold and; (ii) License Fee with a breakdown according to identity
of Licensees, countries, the currency of the payment and date of receipt thereof; and (iii) deductions applicable, as provided in the definition of “Net Sales”; (b) a detailed report within twenty one (21) days of an Exit
Event specifying the nature of the Exit Event, the consideration to be received by the Company or its shareholders in connection with such Exit Event and all other substantial terms and details of such Exit Event and enclose to the report any
agreement executed in connection with such Exit Event immediately following the execution thereof; and (iv) any other matter, data and documents reasonably required by THM and existing with VBL in order to calculate and/or verify the amounts
payable hereunder; and (c)Within four months after the end of each fiscal year, the Company will provide THM with a detailed report, certified by VBL’s Chairman of the Board and by its independent auditor, stating all amounts due to THM
pursuant to this clause 4 in the reported year including relevant invoices issued and all invoices and all payments received by the Company with respect to details specified in the above reports; 21 days prior to an Exit Event he material terms of
such Exit will be disclosed orally by the legal counsel of VBL to the head of THM. 

  

	 	4.9	The Company shall keep and shall cause Licensees to keep complete, accurate and correct books of account and records consistent with sound business and accounting principles and practices. 

 

	 	4.10	Following the First Commercial Sale, THM shall be entitled to appoint an independent auditor selected by it to inspect, after coordination with VBL and during VBL’s regular business hours, all records, and
documents of VBL as may contain information bearing upon the amounts payable to THM under this clause 4. The Company shall take all steps necessary so that all such books of account, records and other documentation of VBL and its Licensees and
Affiliates are available for inspection as aforesaid for each of the Company and its Licensees and Affiliates. The cost of such auditing shall be borne by VBL if the audit uncovers an underreporting of the corresponding amounts owed to THM by more
than ten percent (10%). Otherwise, such costs and expenses shall be borne by THM. VBL shall remedy such discrepancy and pay (i) the shortfall within thirty (30) days of the date of discovery; and (ii) interest thereon at the rate of
4% above the London Interbank Offered Rate (LIBOR) applicable to a 12 month USD deposit, as such rate shall be in effect on each Disbursement Date. The Interest shall be compounded annually and computed on the basis of a 360 day year.

  
 8 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

	 	4.11	Upon THM’s request but not more than once every six months, the Company shall provide THM with a progress report specifying the following details, as updated from the last report: (i) the activities the
Company conducted for the development of Products; and (ii) sales and marketing efforts. 

  

	5.	INDEMNITY 

  

	 	5.1	VBL undertakes to indemnify and hold harmless THM, the Fund, the Hospital, the State of Israel, and their employees, representatives, agents and contractors (the “THM Beneficiaries”) against and from
any loss, liability, claims, damages or expenses of whatever kind or nature incurred by or imposed upon the THM Beneficiaries, to the extent arising out of or resulting from (i) the use and/or exploitation of the Company’s IP or any use of
any products incorporating the Company’s IP or any part thereof and/or manufactured or developed based upon the Company’s IP; and (ii) to the extent that it is based on a claim that the Company’s IP, the Products or other
material produced or developed or marketed by or on behalf of VBL or any of its Affiliates or Licensee infringes any third party’s intellectual property rights including copyright, trade secret, patent, trademark (a “THM
Claim”). 

  

	 	5.2	     

  

	 	5.3	The following mechanism shall apply to any THM Claim pursuant to clause 5.1. If any THM Beneficiary receives notice of any THM Claim, such THM Beneficiary shall, as promptly as is reasonably
possible, give VBL notice of such THM Claim. The failure to give such notice promptly shall relieve VBL of any indemnification obligation it may have hereunder to the extent such failure diminishes its ability to respond to or to defend the
Beneficiary against such THM Claim. VBL shall exclusively assume the defence or represent the interests of the THM Beneficiary in respect of such THM Claim, that shall include the right to select and direct legal counsel and other
consultants to appear in proceedings on behalf of the THM Beneficiary and to propose, accept or reject offers of settlement, all at its sole cost and discretion. 

  

	 	5.4	VBL, at its own expense, shall maintain insurance in an amount consistent with industry standards which provides VBL adequate coverage for (i) performing clinical studies of the Product in humans, (ii) product
liability and (iii) commercial sales of applicable and relevant Products. 

  

	6.	PATENT RIGHTS 

 In the event that the Company decides to abandon its patents in all
applicable jurisdictions in connection with its intent to stop its entire business activities of either of its two business units, then with respect to such Patent Rights that are included in the Company’s IP, the Company will inform THM
(“VBL Notice”) of its intention prior to the abandonment of any such Patent Rights. 

  
 9 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

 THM shall have the right to continue to support and maintain any such Patent Rights provided that it notifies VBL
of its intention within 30 days following the receipt of VBL Notice, and provided further that within 60 days following the notice by THM, the parties reach an agreement for the assignment or license of such Patent Rights to THM. The parties shall
negotiate such agreement in good faith. The parties further agree that such agreement shall provide VBL with payments similar to those set forth in clause 4 and that any such agreement shall be subject to any limitations and restrictions imposed by
applicable third parties, including without limitation, the Office of the Chief Scientist and shall be subject to the assumption by THM of any repayment obligations thereto. THM right hereunder shall lapse and be of no further force and effect, in
the event that THM fails to timely respond to VBL Notice, indicates that it is not interested in the Patent Rights or otherwise the parties fail to reach an agreement as aforesaid during the 90 day period. 

 

	7.	MISCELLANEOUS  

  

	 	7.1	Law and Venue. All disputes arising in connection with this Agreement shall be settled amicably in the first instance. If amicable settlement cannot be reached by the Parties within 15 (fifteen) days from the day
either Party approached the other Parties specifying the essence of the dispute, the dispute shall be settled by 1 (one) arbitrator. If the Parties fail to reach an agreement on the nomination of the arbitrator within 30 (thirty) days of the date
when the claimant’s request for arbitration was communicated by the other Parties, the appointment shall be made by the Head of the Israel Bar. The arbitration will be conducted in Tel Aviv, Israel. The Parties shall be entitled to seek interim
measures of protection in the form of pre-award attachment of assets or injunctive relief. The tribunal shall issue a reasoned award. Such award may grant any relief appropriate under applicable law including without limitation declaratory relief
and/or specific performance. As part of its award the tribunal may award attorneys fees and costs to the prevailing party. The award of the arbitrator shall be final and binding upon the Parties, but subject to appeal, with respect to the disputes
so submitted and the costs of such arbitration. The law that shall apply shall be the statutes and laws of the State of Israel. 

  

	 	7.2	Use of Names. The Company shall not use the names of the State Of Israel, Hospital, the Fund and/or THM and/or their employees, representatives, agents and contractors in any manner or in any publication
including commercial publicity, without the prior written consent of THM. 

  

	 	7.3	Assignment. This Agreement shall be personal to the parties and therefore the Parties may not assign any of their rights or obligations hereunder without the prior written consent of the other party.
Notwithstanding the aforementioned, THM shall be entitled to assign the right to receive payments under this Agreement to any association and/or organization and or company that was established in connection with or for the benefit of the Hospital.
In addition, VBL may, without the consent of THM, assign this Agreement and the rights, obligations and interests of VBL, in whole, to any purchaser of all or substantially all of its assets, or to any successor corporation resulting from any merger
or consolidation of VBL with or into such corporation, provided that any such assignee agrees in writing to be bound by all the terms of this Agreement. 

  
 10 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

	 	7.4	Notices. Except as otherwise provided in this Agreement, all notices permitted or required by this Agreement shall be in writing and shall be deemed to have been duly served (i) upon personal delivery
(ii) upon facsimile transmission (receipt of which has been orally confirmed by the recipient) or (iii) Seven (7) business days after deposit, postage prepaid, return receipt requested, if sent by Registered Mail and addressed to the
address of the parties first above stated or in accordance with such other address information as the party to receive notice may provide in writing to the other party in accordance with the above notice provisions. Any notice given by any other
method will be deemed to have been duly served upon receipt thereof. 

  

	 	7.5	Waivers. No course of dealing in respect of, nor any omission or delay in the exercise of, any right, power, or privilege by either Party shall operate as a waiver thereof, nor shall any single or partial
exercise thereof preclude any further or other exercise thereof or of any other, as each such right, power, or privilege may be exercised either independently or concurrently with others and as often and in such order as each party may deem
expedient. 

  

	 	7.6	Entire Agreement; Amendments. This Agreement, including, without limitation, its schedules, contains the entire agreement of the parties with respect to its subject matter. No oral or prior written statements or
representations not incorporated herein shall have any force or effect, nor shall any part of this Agreement be amended, supplemented, waived or otherwise modified except in a writing signed by both parties. 

 

	 	7.7	Confidentiality. Each party undertakes to the other party that all confidential information disclosed by a party to the other party hereunder or as a result of this Agreement, including the terms and conditions
set forth herein, will be kept in the strictest confidence and will not, without the prior written consent of the disclosing party, be used by the receiving party or be disclosed to, or discussed with, any third party whatsoever. The above
undertaking of confidentiality will not apply to information which: (i) is in the public domain at the time of disclosure; or (ii) subsequently becomes part of the public domain, except by breach by the receiving party of its obligations,
or (iii) is received from a third party who is not under an obligation of confidentiality to the disclosing party. VBL may disclose, on a confidential basis, the terms of this Agreement to its Board of Directors, shareholders, potential
investors, acquirers or licensees in the process of due diligence reviews of its contracted obligations, assets and undertakings. 

  

	 	7.8	THM hereby declares that Sheba’s management reached an understanding with the management of Tel Aviv University (“TAU”), that as between the Hospital and TAU, inventions of TAU professors who work
as medical doctors for Sheba such as Prof. Dror Charats, Prof. Shoenfeld and Prof. Gerge Jacob, shall belong to Sheba. 

  
 11 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

 [Remainder of the Page was left intentionally blank] 

  
 12 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and each of the
undersigned hereby warrants and represents that it has been and is, on the date of this Agreement, duly authorized by all necessary and appropriate action to execute this Agreement. 

 

											
	Tel Hashomer - Medical Research,	 		 		 	Vascular Biogenics Ltd.
	Infrastructure and Services Ltd.	 		 		 	
						
	By:	 	 [Illegible]
	 		 		 	By:	 	 /s/ Dror Harats

					
	 /s/ Dror Harats

Prof. Dror Harats
	 		 		 		 	
					
	Approved and Acknowledged	 		 		 		 	
					
	 [Illegible]

The Government of Israel
 By the Ministry of Health
	 		 		 		 	

  
 13 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

 Appendix A 

INVENTORS 
 1. Prof. Dror Harats

 2. Shoenfeld Yehuda 
 3. George Jacob 

4. Halperin Gideon – up to 2003 
 5. Bloom Nira 

6. Greenberger Shoshana 
 7. Tal Reshef 

8. Peled Michael 
  

	*	detailed list of inventions is provided under Appendix B. 

  
  

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

 Appendix B’ up to 3 Feb 2013 

 

																	
	 METHODS AND COMPOSITIONS FOR ENHANCING TARGETING OF VIRAL VECTORS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
									
	 [* * *]
	  		  		  		  		  		  		  		  	

  

																	
	 ISOLATED POLYNUCLEOTIDES AND NUCLEIC ACID CONSTRUCTS FOR DIRECTING EXPRESSION OF A GENE-OF-INTEREST IN CELLS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry
Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
									
	 [* * *]
	  		  		  		  		  		  		  		  	
									
	 52423
	  	PCT	  	19-Oct-2010	  		  	12/10/2011	  		  	3182.041PC01	  	Pending	  	

  

																	
	 TREATMENT WITH VB-201
  

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry
Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	 [* * *]
	  		  		  		  		  		 		  		  	
	 50378
	  	PCT	  	05-Jan-2010
 61/292,226
	  		  	05-Jan-2011
 IL2011/000012
	  	Publ. Date: 14-Jul-2011

Publ. #: WO2011/083469
	 	3182.018PC05	  	Expired	  	YACOV Niva; BREITBART
 Eyal; MENDEL Itzhak; FEIGE

Erez; COHEN Yael

  
  

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 PAF-LIKE HOMOLOGS AND USES THEREOF
  

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	 44504
	  	PCT	  	16-Oct-2007
 60/960,846
	  		  	05-Oct-2008
 IL2008/001315
	  	Publ. Date: 23-Apr-2009

Publ. #: WO2009/050692
	 		  	Expired	  	YACOV Niva; BREITBART
Eyal; MENDEL Itzhak
	 48215
	  	Israel
 NP
	  	16-Oct-2007
 60/960,846
	  	15-Apr-2010	  	05-Oct-2008
 205144
	  		 	3182.019IL01	  	Aban	  	YACOV Niva; BREITBART
Eyal; MENDEL Itzhak
	 48216
	  	USA
 NP
	  	16-Oct-2007
 60/960,846
	  	15-Apr-2010	  	05-Oct-2008
 12/738,097
	  		 	3182.0190001	  	Aban	  	YACOV Niva; BREITBART
Eyal; MENDEL Itzhak
	 48217
	  	Europe
 NP
	  	16-Oct-2007
 60/960,846
	  	14-May-2010	  	05-Oct-2008
 08808113.8
	  		 	3182.019EP01	  	Aban	  	YACOV Niva; BREITBART
Eyal; MENDEL Itzhak

  

																	
	 IMPROVED SYNTHESIS OF OXIDIZED PHOSPHOLIPIDS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		  		  		  	

  
 3 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 28367
	  	PCT	  	09-Jul-2004
 60/586,219
	  		  	10-Jul-2005
 IL2005/000735
	  	Publ. Date: 19-Jan-2006

Publ. #: WO2006/006161
	 		  	Expired	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33799
	  	Israel
 NP
	  	09-Jul-2004
 60/586,219
	  	09-Jan-2007	  	10-Jul-2005	  	1-Mar-2012
 180628
	 	3182.020IL00	  	GRANTED	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 50430
	  	Israel
 DIV
	  	09-Jul-2004
 60/586,219
	  	17-Mar-2011	  	10-Jul-2005
 211795
	  		 		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 50431
	  	Israel
 DIV
	  	09-Jul-2004
 60/586,219
	  	17-Mar-2011	  	10-Jul-2005
 211796
	  		 		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33793
	  	Europe
 NP
	  	09-Jul-2004
 60/586,219
	  	09-Feb-2007	  	10-Jul-2005
 05758938.4
	  		 		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33793 Div
	  	Europe
 Div
	  	09-Jul-2004
 60/586,219
	  	Oct 2012	  	10-Jul-2005	  		 	3182.020EP10	  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33793 Div
	  	Europe
 Div
	  	09-Jul-2004
 60/586,219
	  	Oct 2012	  	10-Jul-2005
 12179533.0
	  		 	3182.020EP20	  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 39643
	  	Hong Kong
 NP
	  	09-Jul-2004
 60/586,219
	  	31-May-2007	  	10-Jul-2005
 07105789.7
	  		 		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33795
	  	Canada
 NP
	  	09-Jul-2004
 60/586,219
	  	09-Jan-2007	  	10-Jul-2005
 2,573,396
	  		 		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

  
 4 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 33796
	  	Japan
 NP
	  	09-Jul-2004
 60/586,219
	  	09-Jan-2007	  	10-Jul-2005
 2007-519983
	  	24-Jun-2011
 4,767,948
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 48896
	  	Japan
 DIV
	  	09-Jul-2004
 60/586,219
	  	21-May-2010	  	10-Jul-2005
 2010-116964
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33797
	  	Republic of Korea
 NP
	  	09-Jul-2004
 60/586,219
	  	09-Feb-2007	  	10-Jul-2005
 2007-7003288
	  	9-Nov-2012
 10-1201935
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33798
	  	China
 NP
	  	09-Jul-2004
 60/586,219
	  	28-Feb-2007	  	10-Jul-2005
 200580029218.9
	  	3-Aug-2011
 200580029218.9
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 48018
	  	China
 DIV
	  	09-Jul-2004
 60/586,219
	  	11-Feb-2010	  	10-Jul-2005
 201010128184.1
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 33801
	  	Russian Federation
 NP
	  	09-Jul-2004
 60/586,219
	  	09-Feb-2007	  	10-Jul-2005
 2007105097
	  	20-Sep-2010
 2399626
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33802
	  	Mexico
 NP
	  	09-Jul-2004
 60/586,219
	  	08-Jan-2007	  	10-Jul-2005
 MX/a/2007/000361
	  	17-Mar-2011
 284830
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33803
	  	Australia
 DIV
	  	09-Jul-2004
 60/586,219
	  	09-Jan-2007	  	10-Jul-2005
 2007200090
	  	2007200090
 5 Jan 2012
	  	3182.020AU00	  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 50536
	  	Mexico
 DIV
	  	09-Jul-2004
 60/586,219
	  	14-Jan-2011	  	10-Jul-2005
 MX/a/2011/000630
	  	3 Sep 2012
 303011
	  		  	Granetd	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

  
 5 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 33804
	  	New Zealand
 NP
	  	09-Jul-2004
 60/586,219
	  	09-Feb-2007	  	10-Jul-2005
 553147
	  	06-Nov-2010
 553147
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 48999
	  	New Zealand
 DIV
	  	09-Jul-2004
 60/586,219
	  	29-Jun-2010	  	10-Jul-2005
 586503
	  	10 Oct 2011
 586503
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33805
	  	South Africa
 NP
	  	09-Jul-2004
 60/586,219
	  		  	10-Jul-2005
 2007/01178
	  	25-Sep-2008
 2007/01178
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

  

																	
	 PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
	 02/23345
	  	USA
 CIP
	  	17-Nov-2000
 60/248,582
	  		  	01-May-2002
 10/135,447
	  	27-Jun-2006
 7,067,649
	  		  	Granted	  	HARATS Dror; BREITBART
Eyal; BLOOM Nira
	 28786
	  	USA
 DIV
	  	17-Nov-2000
 60/248,582
	  	29-Oct-2004	  	01-May-2002
 10/975,619
	  	25-Aug-2009
 7,579,327
	  		  	Granted	  	HARATS Dror; BREITBART
Eyal; BLOOM Nira
	 45023
	  	USA
 DIV
	  	17-Nov-2000
 60/248,582
	  	03-Jun-2009	  	01-May-2002
 12/457,200
	  		  		  	Pending	  	HARATS Dror; BREITBART
Eyal; BLOOM Nira
	 50926
	  	USA
 DIV
	  	17-Nov-2000
 60/248,582
	  	27-Apr-2011	  	01-May-2002
 13/094,900
	  		  		  	Pending	  	HARATS Dror; BREITBART
Eyal; BLOOM Nira
	 53777
	  	USA
 DIV
	  	17-Nov-2000
 60/248,582
	  	24-April
2012	  	01-May-2002
 13/454,171
	  		  	3182.0350004	  	Pending	  	HARATS Dror; BREITBART
Eyal; BLOOM Nira

  
 6 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 25974
	  	PCT	  	01-May-2002
 10/135,447
	  		  	30-Apr-2003
 IL03/00347
	  	Publ. Date: 13-Nov-2003
 Publ. #:
WO03/093409
	 		  	Expired	  	HARATS
Dror
	 28650
	  	Singapore
 NP
	  	01-May-2002
 10/135,447
	  	01-Nov-2004	  	30-Apr-2003
 200406381-4
	  	30-May-2008
 107841 [WO 03/093409]
	 		  	Granted	  	HARATS
Dror;
BREITBART
Eyal;
BLOOM
Nira
	 28655
	  	South Africa
 NP
	  	01-May-2002
 10/135,447
	  	05-Nov-2004	  	30-Apr-2003
 2004/8989
	  	26-Jul-2006
 2004/8989
	 		  	Granted	  	HARATS
Dror;
BREITBART
Eyal;
BLOOM
Nira
	 [* * *]
	  		  		  		  		  		 		  		  	
	 [* * *]
	  		  		  		  		  		 		  		  	
	 28646
	  	Japan
 NP
	  	01-May-2002
 10/135,447
	  	01-Nov-2004	  	30-Apr-2003
 2004-501545
	  		 		  	Abandoned	  	HARATS
Dror
	 [* * *]
	  		  		  		  		  		 		  		  	
	 [* * *]
	  		  		  		  		  		 		  		  	
	 [* * *]
	  		  		  		  		  		 		  		  	
	 28651
	  	Canada
 NP
	  	01-May-2002
 10/135,447
	  	01-Nov-2004	  	30-Apr-2003
 2,483,996
	  		 		  	Abandoned	  	HARATS
Dror;
BREITBART
Eyal;
BLOOM
Nira
	 28652
	  	Mexico
 NP
	  	01-May-2002
 10/135,447
	  	28-Oct-2004	  	30-Apr-2003
 PA/a/2004/010711
	  		 		  	Abandoned	  	HARATS
Dror;
BREITBART
Eyal;
BLOOM
Nira
	 [* * *]
	  		  		  		  		  		 		  		  	

  
 7 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

 COMBINED TREATMENT UTILIZING VB-201 

 

																	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	 50379
	  	PCT	  	05-Jan-2010
 61/292,226
	  		  	05-Jan-2011
 IL2011/000010
	  	Publ. Date: 14-Jul-2011

Publ. #: WO2011/083467
	 		  	Expired	  	YACOV Niva; BREITBART
Eyal; COHEN Yael
		  	US
NP	  	05-Jan-2010
 61/292,226
	  	5-July 2012	  	05-Jan-2011
 13/520,713
	  		 	3182.0160005	  	Pending	  	YACOV Niva; BREITBART
Eyal; COHEN Yael
		  	EP
NP	  	05-Jan-2010
 61/292,226
	  	1-Aug 2012	  		  		 	3182.016EP05	  	Pending	  	YACOV Niva; BREITBART
Eyal; COHEN Yael
		  	JP
NP	  	05-Jan-2010
 61/292,226
	  	4-July 2012	  		  		 	3182.016JP05	  	Pending	  	YACOV Niva; BREITBART
Eyal; COHEN Yael

  

																	
	 POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME AND USE THEREOF IN THE TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH
ISCHEMIA
  

	 Our
Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	 41795
	  	PCT	  	31-Jul-2006
 60/834,157
	  		  	31-Jul-2007
 IL2007/000959
	  	Publ. Date: 07-Feb-2008

Publ. #: WO/2008/015675
	 		  	Expired	  	TAL Reshef; BREITBART Eyal;
BANGIO Livnat
	 45501
	  	China
 NP
	  	31-Jul-2006
 60/834,157
	  	26-Mar-2009	  	31-Jul-2007
 200780035863.0
	  	8-Aug 2012
 ZL20078003 5863.0
	 	3182.040CN01	  	Granted	  	TAL Reshef; BREITBART Eyal;
BANGIO Livnat

  
 8 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 54283
	  	China
 Div
	  	31-Jul-2006
 60/834,157
	  	26-June-2012	  	31-Jul-2007
 201210210646.3
	  		  	3182.040CN11	  	Pending	  	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 45495
	  	USA
 NP
	  	31-Jul-2006
 60/834,157
	  	02-Feb-2009	  	31-Jul-2007
 12/309,856
	  		  		  	Abandoned	  	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 51521
	  	USA
 DIV
	  	31-Jul-2006
 60/834,157
	  	20-Jun-2011	  	31-Jul-2007
 13/163,776
	  		  		  	Pending	  	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 45496
	  	Israel
 NP
	  	31-Jul-2006
 60/834,157
	  	29-Jan-2009	  	31-Jul-2007
 196792
	  		  		  	Pending	  	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 45499
	  	Australia
 NP
	  	31-Jul-2006
 60/834,157
	  	02-Feb-2009	  	31-Jul-2007
 2007280017
	  	26-July 2012
 2007280017
	  	3182.040AU01	  	Granted	  	TAL Reshef; BREITBART Eyal;
BANGIO Livnat
	 54370
	  	Australia
 Div
	  	31-Jul-2006
 60/834,157
	  	12-July 2012	  	31-Jul-2007
 2012204128
	  		  	3182.040AU11	  	Pending	  	TAL Reshef; BREITBART Eyal;
BANGIO Livnat
	 45500
	  	Japan
 NP
	  	31-Jul-2006
 60/834,157
	  	02-Feb-2009	  	31-Jul-2007
 2009-522416
	  		  		  	Pending	  	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 45502
	  	Republic of Korea
 NP
	  	31-Jul-2006
 60/834,157
	  	27-Feb-2009	  	31-Jul-2007
 2009-7004288
	  		  		  	Abandoned	  	TAL Reshef; BREITBART Eyal;
BANGIO Livnat

  
 9 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 45503
	  	Mexico
 NP
	  	31-Jul-2006
 60/834,157
	  	29-Jan-2009	  	31-Jul-2007
 MX/a/2009/001157
	  		 		  	Pending	  	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 45504
	  	New Zealand
 NP
	  	31-Jul-2006
 60/834,157
	  	26-Jan-2009	  	31-Jul-2007
 574410
	  	9 July 2012
 574410
	 	3182.040NZ01	  	Granted	  	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 45505
	  	South Africa
 NP
	  	31-Jul-2006
 60/834,157
	  	26-Jan-2009	  	31-Jul-2007
 2009/00581
	  	31-Mar-2010
 2009/00581
	 		  	Granted	  	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 45506
	  	Singapore
 NP
	  	31-Jul-2006
 60/834,157
	  	30-Jan-2009	  	31-Jul-2007
 200900642-0
	  	30-Jun-2011
 149616[WO2008/015675]
	 		  	Granted	  	TAL Reshef; BREITBART Eyal;
BANGIO Livnat

  

																	
	 TREATMENT WITH VB-201
  

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	 [* * *]
	  		  		  		  		  		 		  		  	
	 50377
	  	PCT	  	05-Jan-2010
 61/292,226
	  		  	05-Jan-2011
 IL2011/000008
	  	Publ. Date: 14-Jul-2011

Publ. #: WO2011/083465
	 		  	Expired	  	YACOV Niva; BREITBART
Eyal; MENDEL Itzhak; SHER
Naamit; COHEN Yael
		  	US NP	  	05-Jan-2010
 61/292,226
	  	June 2012	  	05-Jan-2011	  		 	3182.0170005	  	Pending	  	
		  	AU NP	  	05-Jan-2010
 61/292,226
	  	June 2012	  	05-Jan-2011	  		 	3182.017AU05	  	Pending	  	

  
 10 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 [* * *]
	  		  		  		  		  		  		  		  	
		  	CANADA
NP	  	05-Jan-2010
 61/292,226
	  	June 2012	  	05-Jan-2011	  		  	3182.017CA05	  	Pending	  	
		  	China
 NP
	  	05-Jan-2010
 61/292,226
	  	June 2012	  	05-Jan-2011	  		  	3182.017CN05	  	Pending	  	
		  	HK
 NP
	  	05-Jan-2010
 61/292,226
	  	June 2012	  	05-Jan-2011	  		  	3182.017HK05	  	Pending	  	
		  	EP NP	  	05-Jan-2010
 61/292,226
	  	June 2012	  	05-Jan-2011	  		  	3182.017EP05	  	Pending	  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
		  	Japan
 NP
	  	05-Jan-2010
 61/292,226
	  	June 2012	  	05-Jan-2011	  		  	3182.017JP05	  	Pending	  	
		  	South Korea
 NP
	  	05-Jan-2010
 61/292,226
	  	June 2012	  	05-Jan-2011	  		  	3182.017KR05	  	Pending	  	
		  	MX
 NP
	  	05-Jan-2010
 61/292,226
	  	June 2012	  	05-Jan-2011	  		  	3182.017MX05	  	Pending	  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	

  
 11 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

 ANTI-ANGIOGENIC ADENOVIRUS VECTOR SUITABLE FOR CLINICAL APPLICATIONS AND METHODS FOR PRODUCTION THEREOF

  

																	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	  
 METHODS OF PRODUCING ADENOVIRUS VECTORS AND VIRAL
PREPARATIONS GENERATED THEREBY
  

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 49684
	  	PCT	  	12-Jan-2010
 61/294,158
	  		  	12-Jan-2011
 IB2011/050137
	  	Publ. Date: 21-Jul-2011

Publ. #: WO2011/086509
	 		  	Expired	  	BREITBART
Eyal;
BANGIO
Livnat;
SHER
Naamit
		  	US NP	  	12-Jan-2010
 61/294,158
	  	June 2012	  	12-Jan-2011	  		 	3182.0330001	  	Pending	  	BREITBART
Eyal;
BANGIO
Livnat;
SHER
Naamit
		  	EP NP	  	12-Jan-2010
 61/294,158
	  	June 2012	  	12-Jan-2011	  		 	3182.033EP01	  	Pending	  	BREITBART
Eyal;
BANGIO
Livnat;
SHER
Naamit
	 [* * *]
	  		  		  		  		  		 		  		  	
		  	JP NP	  	12-Jan-2010
 61/294,158
	  	June 2012	  	12-Jan-2011	  		 	3182.033JP01	  	Pending	  	BREITBART
Eyal;
BANGIO
Livnat;
SHER
Naamit
	 [* * *]
	  		  		  		  		  		 		  		  	

  
 12 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

 IMMUNOMODULATION (IMMUNIZATION AND TOLERANCE) OF APO-E DEFICIENT MICE WITH 1 HEXADECINYL 2-5’ OXOPENTYL
PHOSPHATIDYCHLOLINE (2-5 ALLE-ALDEHYDE LECITIN ETHER) SUPPRESSES EARLY ATHEROGENESIS 
  

																	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	  
 METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED
OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS
  

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 01/22753
	  	PCT	  	24-Nov-2000
 60/252,574
	  		  	22-Nov-2001
 IL01/01080
	  	Publ. Date: 30-May-2002
 Publ. #:
WO02/41827
	 		  	Expired	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 26035
	  	Europe
 NP
	  	22-Nov-2000
 60/252,574
	  	15-May-2003	  	22-Nov-2001
 01997274.4
	  		 		  	Pending	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 52529
	  	EP Div	  	22-Nov-2000
 60/252,574
	  	17-Nov 2011	  	22-Nov-2001
 11189562.9
	  		 	3182.021EP11	  	Pending	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 27265
	  	Hong Kong
 NP
	  	24-Nov-2000
 60/252,574
	  	12-Dec-2003	  	22-Nov-2001
 03109096.1
	  		 		  	Pending	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 26036
	  	Israel
 NP
	  	22-Nov-2000
 60/252,574
	  	20-May-2003	  	22-Nov-2001
 156015
	  	10-May-2008
 156015
	 		  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 32434
	  	Israel
 DIV
	  	24-Nov-2000
 60/252,574
	  	20-Jul-2006	  	22-Nov-2001
 176976
	  	1-Dec 2012
 176976
	 	3182.021IL11	  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 26037
	  	India
 NP
	  	22-Nov-2000
 60/252,574
	  	22-May-2003	  	22-Nov-2001
 796/CHENP/2003
	  	19-Sep-2008
 223638
	 		  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon

  
 13 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 26039
	  	Canada
 NP
	  	22-Nov-2000
 60/252,574
	  	22-May-2003	  	22-Nov-2001
 2,429,817
	  		  	3182.021CA01	  	Pending	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 26040
	  	Australia
 NP
	  	22-Nov-2000
 60/252,574
	  	23-May-2003	  	22-Nov-2001
 2002218461
	  	21-Dec-2006
 2002218461
	  		  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 26041
	  	Japan
 NP
	  	22-Nov-2000
 60/252,574
	  	23-May-2003	  	22-Nov-2001
 2002-544008
	  	01-Aug-2008
 4,162,486
	  		  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 44299
	  	Japan
 DIV
	  	24-Nov-2000
 60/252,574
	  	10-Jun-2008	  	22-Nov-2001
 2008-151301
	  	25 May 2012
 5001906
	  		  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 26042
	  	China
 NP
	  	22-Nov-2000
 60/252,574
	  	22-Jul-2003	  	22-Nov-2001
 01822215.3
	  	06-Jan-2010
 ZL01822215.3
	  		  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 26043
	  	Republic of Korea
 NP
	  	22-Nov-2000
 60/252,574
	  	24-May-2003	  	22-Nov-2001
 2003-7006991
	  	17-Oct-2008
 865142
	  		  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 26044
	  	Mexico
 NP
	  	22-Nov-2000
 60/252,574
	  	22-May-2003	  	22-Nov-2001
 PA/a/2003/004517
	  	02-Sep-2009
 269738
	  		  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 46494
	  	Mexico
 DIV
	  	24-Nov-2000
 60/252,574
	  	12-Jun-2009	  	22-Nov-2001
 MX/a/2009/006365
	  	2 December 2011
 293020
	  	3182.021MX11	  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon

  
 14 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 36194
	  	USA
 CIP
	  	17-Nov-2000
 60/248,582
	  		  	30-Apr-2007
 11/790,992
	  		 		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 43177
	  	PCT	  	30-Apr-2007
 11/790,992
	  		  	27-Apr-2008
 IL2008/000543
	  	Publ. Date: 06-Nov-2008

Publ. #: WO2008/132729
	 		  	Expired	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART
Eyal; BANGIO Livnat;
PELED Michael
	 47030
	  	Europe
 NP
	  	30-Apr-2007
 11/790,992
	  	27-Nov-2009	  	27-Apr-2008
 08738245.3
	  		 		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 48882
	  	Hong Kong
 NP
	  	30-Apr-2007
 11/790,992
	  	11-Jun-2010	  	27-Apr-2008
 10105838.3
	  		 		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 47031
	  	Japan
 NP
	  	30-Apr-2007
 11/790,992
	  	30-Oct-2009	  	27-Apr-2008
 2010-505002
	  		 		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 47032
	  	Canada
 NP
	  	30-Apr-2007
 11/790,992
	  	27-Oct-2009	  	27-Apr-2008
 2,685,394
	  		 		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 47033
	  	China
 NP
	  	30-Apr-2007
 11/790,992
	  	30-Dec-2009	  	27-Apr-2008
 200880022935.2
	  		 	3182.039CN01	  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael

  
 15 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 47034
	  	Australia
 NP
	  	30-Apr-2007
 11/790,992
	  	27-Nov-2009	  	27-Apr-2008
 2008243817
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 47035
	  	Republic of Korea
 NP
	  	30-Apr-2007
 11/790,992
	  	18-Nov-2009	  	27-Apr-2008
 2009-7024041
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 [* * *]
	  		  		  		  		  		  		  		  	
	 47037
	  	Israel
 NP
	  	30-Apr-2007
 11/790,992
	  	26-Oct-2009	  	27-Apr-2008
 201760
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 47038
	  	Mexico
 NP
	  	30-Apr-2007
 11/790,992
	  	29-Oct-2009	  	27-Apr-2008
 MX/a/2009/011750
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 47039
	  	New Zealand
 NP
	  	30-Apr-2007
 11/790,992
	  	27-Nov-2009	  	27-Apr-2008
 581511
	  	5 June 2012
 581511
	  	3182.039NZ01	  	Granetd	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 47040
	  	South Africa
 NP
	  	30-Apr-2007
 11/790,992
	  	25-Nov-2009	  	27-Apr-2008
 2009/08331
	  	29-Dec-2010
 2009/08331
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 47041
	  	Singapore
 NP
	  	30-Apr-2007
 11/790,992
	  	30-Oct-2009	  	27-Apr-2008
 200907209-1
	  	15 May 2012
 156740
	  	3182.039SG01	  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael

  
 16 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

 THE EFFECT OF MUCOSAL TOLERANCE WITH LIPID IPOPROTEIN AND PROTEIN ANTIGENS ON ATHEROSCLEROSIS IN LDL-RECEPTOR
DEFICIENT MICE 
  

																	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	  
 METHODS EMPLOYING AND COMPOSITIONS CONTAINING PLAQUE
ASSOCIATED MOLECULES FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS
  

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 01/23033
	  	PCT	  	04-Jan-2001
 60/259,512
	  		  	03-Jan-2002
 IL02/00005
	  	Publ. Date: 11-Jul-2002
 Publ. #:
WO02/053092
	 		  	Expired	  	HARATS Dror; GEORGE
Jacob
	 26046
	  	Israel
 NP
	  	04-Jan-2001
 60/259,512
	  	03-Jul-2003	  	03-Jan-2002
 156770
	  		 		  	Allowed	  	HARATS Dror; GEORGE
Jacob
	 26047
	  	India
 NP
	  	04-Jan-2001
 60/259,512
	  	04-Jul-2003	  	03-Jan-2002
 1044/CHENP/2003
	  	19-Sep-2008
 223640
	 		  	Granted	  	HARATS Dror; GEORGE
Jacob
	 26048
	  	USA
 NP
	  	04-Jan-2001
 60/259,512
	  	02-Jul-2003	  	03-Jan-2002
 10/451,370
	  	09-Oct-2007
 7,279,459
	 		  	Granted	  	HARATS Dror; GEORGE
Jacob
	 26050
	  	Australia
 NP
	  	04-Jan-2001
 60/259,512
	  	11-Jul-2003	  	03-Jan-2002
 2002225301
	  	03-Mar-2006
 2002225301
	 		  	Granted	  	HARATS Dror; GEORGE
Jacob
	 26051
	  	Japan
 NP
	  	04-Jan-2001
 60/259,512
	  	03-Jul-2003	  	03-Jan-2002
 2002-554043
	  	26-Sep-2008
 4,191,997
	 		  	Granted	  	HARATS Dror; GEORGE
Jacob
	 26052
	  	China
 NP
	  	04-Jan-2001
 60/259,512
	  	04-Sep-2003	  	03-Jan-2002
 02805950.6
	  		 		  	Pending	  	HARATS Dror; GEORGE
Jacob

  
 17 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 26054
	  	Mexico
 NP
	  	04-Jan-2001
 60/259,512
	  	01-Jun-2003	  	03-Jan-2002
 PA/a/2003/006043
	  	17-Mar-2009
 265173
	  		  	Granted	  	HARATS Dror; GEORGE
Jacob
	 26045
	  	Europe
 NP
	  	04-Jan-2001
 60/259,512
	  	18-Jul-2003	  	03-Jan-2002
 02715682.7
	  		  		  	Abandoned	  	HARATS Dror; GEORGE
Jacob
	 27463
	  	Hong Kong
 NP
	  	04-Jan-2001
 60/259,512
	  	28-Jan-2004	  	03-Jan-2002
 04100565.1
	  		  		  	Abandoned	  	HARATS Dror; GEORGE
Jacob
	 26049
	  	Canada
 NP
	  	04-Jan-2001
 60/259,512
	  	03-Jul-2003	  	03-Jan-2002
 2,433,781
	  		  		  	Abandoned	  	HARATS Dror; GEORGE
Jacob
	 [* * *]
	  		  		  		  		  		  		  		  	

  

																	
	 FORMULATIONS AND DOSAGE FORMS OF CI-201 AND RELATED COMPOUNDS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
		  	PCT	  	Sept. 1, 2011
 61/529,989
	  		  	Aug. 31, 2012
 PCT/US2012/053533
	  		  	3182.013PC01	  	Pending	  	SHER Naamit; YOUNG Victor
M.; McNAUGHTON Alyn;
WILDING Ian; BAKHSHAEE
Massoud

  
 18 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	 	  	Status	  	Inventor
	 31577
	  	USA
 CIP
	  	17-Nov-2000
 60/248,582
	  		  	23-Feb-2006
 11/359,513
	  	18 October 2011
 8,039,261
	 	3182.0380000	  	Granted	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
BANGIO Livnat; PELED Michael
	 37180
	  	PCT	  	23-Feb-2006
 11/359,513
	  		  	22-Feb-2007
 IL2007/000242
	  	Publ. Date: 30-Aug-2007

Publ. #: WO2007/096882
	 		  	Expired	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat
	 44720
	  	USA
 NP
	  	17-Nov-2000
 60/248,582
	  	20-Aug-2008	  	22-Feb-2007
 12/224,178
	  		 		  	Abandoned	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
BANGIO Livnat; PELED Michael
	 44708
	  	Europe
 NP
	  	23-Feb-2006
 11/359,513
	  	28-Aug-2008	  	22-Feb-2007
 07713267.8
	  		 		  	Pending	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat
	 [* * *]
	  		  		  		  		  		 		  		  	
	 44709
	  	Israel
 NP
	  	23-Feb-2006
 11/359,513
	  	19-Aug-2008	  	22-Feb-2007
 193554
	  		 		  	Abandoned	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat
	 [* * *]
	  		  		  		  		  		 		  		  	
	 44711
	  	Canada
 NP
	  	23-Feb-2006
 11/359,513
	  	20-Aug-2008	  	22-Feb-2007
 2,638,829
	  		 		  	Abandoned	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat

  
 19 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 44712
	  	Australia
 NP
	  	23-Feb-2006
 11/359,513
	  	23-Sep-2008	  	22-Feb-2007
 2007219088
	  		  		  	Abandoned	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat
	 44713
	  	Japan
 NP
	  	23-Feb-2006
 11/359,513
	  	25-Aug-2008	  	22-Feb-2007
 2008-555946
	  		  		  	Abandoned	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat
	 44714
	  	China
 NP
	  	23-Feb-2006
 11/359,513
	  	21-Oct-2008	  	22-Feb-2007
 200780014285.2
	  		  		  	Abandoned	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat
	 44715
	  	Republic of Korea
 NP
	  	23-Feb-2006
 11/359,513
	  	22-Sep-2008	  	22-Feb-2007
 2008-7023144
	  		  		  	Abandoned	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat
	 44716
	  	Mexico
 NP
	  	23-Feb-2006
 11/359,513
	  	22-Aug-2008	  	22-Feb-2007
 MX/a/2008/010859
	  		  		  	Abandoned	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	

  

																	
	 PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
	 33794
	  	USA CIP	  	09-Jul-2004
 60/586,219
	  		  	09-Jan-2007
 11/650,973
	  	05-Oct-2010
 7,807,847
	  	3182.0200001	  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 49396
	  	USA DIV	  	09-Jul-2004
 60/586,219
	  	24-Aug-2010	  	09-Jan-2007
 12/861,921
	  	28-Feb 2012
 8,124,800
	  	3182.0200002	  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

  
 20 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 52800
	  	USA DIV	  	09-Jul-2004
 60/586,219
	  	May 24, 2012	  	January 26, 2012
 13/358,573
	  		  	3182.0200003	  	Pending	  	HALPERIN Gideon;
KOVALEVSKI
		  	USA CIP	  	09-Jul-2004
 60/586,219
	  		  	Nov. 9, 2012
 13/672,811
	  		  	3182.0200004	  	Pending	  	HALPERIN Gideon;
KOVALEVSKI
		  	US CON	  	09-Jul-2004
 60/586,219
	  		  	Dec. 10, 2012
 13/709,198
	  		  	3182.0200005	  	Pending	  	HALPERIN Gideon;
KOVALEVSKI

  

																	
	 IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 43029
	  	PCT	  	09-Jan-2007
 11/650,973
	  		  	02-Jan-2008
 IL2008/000013
	  	Publ. Date: 17-Jul-2008
 Publ. #: WO2008/084472
	 		  	Expired	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 46756
	  	South Africa
 NP
	  	09-Jan-2007
 11/650,973
	  		  	02-Jan-2008
 2009/05601
	  	26-May-2010
 2009/05601
	 		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 46755
	  	New Zealand
 NP
	  	09-Jan-2007
 11/650,973
	  	07-Aug-2009	  	02-Jan-2008
 578947
	  	4-Dec 2011
 578947
	 	3182.020NZ01	  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 51026
	  	New Zealand
 DIV
	  	09-Jan-2007
 11/650,973
	  	15-Jun-2011	  	02-Jan-2008
 593529
	  		 	3182.020NZ11	  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 [* * *]
	  		  		  		  		  		 		  		  	

  
 21 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 46754
	  	Australia
 NP
	  	09-Jan-2007
 11/650,973
	  	07-Aug-2009	  	02-Jan-2008
 2008204238
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 46753
	  	Mexico
 NP
	  	09-Jan-2007
 11/650,973
	  	09-Jul-2009	  	02-Jan-2008
 MX/a/2009/007422
	  	9-Jan 2012
 294470
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 [* * *]
	  		  		  		  		  		  		  		  	
	 46751
	  	Israel
 NP
	  	09-Jan-2007
 11/650,973
	  	09-Jul-2009	  	02-Jan-2008
 199792
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 46750
	  	China
 NP
	  	09-Jan-2007
 11/650,973
	  	31-Aug-2009	  	02-Jan-2008
 200880006707.6
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 46749
	  	Republic of Korea
 NP
	  	09-Jan-2007
 11/650,973
	  	27-Jul-2009	  	02-Jan-2008
 2009-7015780
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 46748
	  	Japan
 NP
	  	09-Jan-2007
 11/650,973
	  	09-Jul-2009	  	02-Jan-2008
 2009-545295
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 46747
	  	Canada
 NP
	  	09-Jan-2007
 11/650,973
	  	06-Jul-2009	  	02-Jan-2008
 2,674,902
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 46746
	  	Europe
 NP
	  	09-Jan-2007
 11/650,973
	  	07-Aug-2009	  	02-Jan-2008
 08700247.3
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
		  	Europe
 Div
	  	09-Jan-2007
 11/650,973
	  	July 27, 2012	  	02-Jan-2008
 EP 12178298.1
	  		  	3182.020EP11	  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 48328
	  	Hong Kong
 NP
	  		  	16-Mar-2010	  	02-Jan-2008
 10102729.2
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

  
 22 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 COMPOSITIONS AND METHODS FOR TREATING GLIOBLASTOMA GBM

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	
	  
 METHODS FOR USE OF A SPECIFIC ANTI-ANGIOGENIC
ADENOVIRAL AGENT
  

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	 50375
	  	PCT	  	05-Jan-2010
 61/282,228
	  		  	05-Jan-2011
 IL2011/000007
	  	Publ. Date: 14-Jul-2011

Publ. #: WO2011/083464
	 		  	Expired	  	BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael
		  	US NP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		 	3182.0310002	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael
		  	EP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		 	3182.031EP02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael
		  	IL	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		 	3182.031IL02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael
	 [* * *]
	  		  		  		  		  		 		  		  	
		  	JP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		 	3182.031JP02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael

  
 23 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 [* * *]
	  		  		  		  		  		  		  		  	
		  	MX	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.031MX02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
		  	Canada	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.031CA02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael
		  	Au	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.031AU02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael

  

																	
	 COMPOSITIONS AND METHODS FOR TREATING GLIOBLASTOMA GBM

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	 50376
	  	PCT	  	05-Jan-2010
 61/282,228
	  		  	05-Jan-2011
 IL2011/000009
	  	Publ. Date: 14-Jul-2011

Publ. #: WO2011/083466
	 	3182.032PC02	  	Expired	  	BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J.

  
 24 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
		  	US NP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.0320002	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J.
		  	EU NP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.032EP02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J.
		  	IL NP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.032IL02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J.
	 [* * *]
	  		  		  		  		  		  		  		  	
		  	JP NP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.032JP02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J.
		  	KR NP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.032KR02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J.
		  	MX NP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.032MX02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J.
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
		  	CA NP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.032CA02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J.
		  	AU NP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.032AU02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J.

  
 25 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	 	  	Status	  	Inventor
	 32516
	  	USA
 CIP
	  	27-May-2003
 10/445,347
	  		  	28-Sep-2006
 11/528,657
	  	01-Dec-2009
 7,625,882
	  		  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN
Gideon; KOVALEVSKI-
ISHAI Eti; YACOV Niva;
MENDEL Itzhak
	 46643
	  	USA
 DIV
	  	27-May-2003
 10/445,347
	  	14-Oct-2009	  	28-Sep-2006
 12/588,371
	  	05-Jul-2011
 7,973,023
	  		  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN
Gideon; KOVALEVSKI-
ISHAI Eti; YACOV Niva;
MENDEL Itzhak
	 50968
	  	USA
 CON
	  	27-May-2003
 10/445,347
	  	13-Apr-2011	  	28-Sep-2006
 13/085,542
	  		  		  	Pending	  	HARATS Dror; GEORGE
Jacob; HALPERIN
Gideon; KOVALEVSKI-
ISHAI Eti; YACOV Niva;
MENDEL Itzhak

  

																	
	 AN IMMUNOLOGICAL AND ORAL TOLERANCE-INDUCING COMPOSITION AND USE THEREOF FOR THE PREVENTION AND/OR FOR THE TREATMENT OF
ATHEROSCLEROSIS
  

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
	 00/21414
	  	Israel
 Basic
	  		  		  	04-Oct-1998
 126447
	  	30-Dec-2004
 126447
	  		  	Granted	  	HARATS Dror; SHOENFELD
Yehuda; GEORGE Jacob

  
 26 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

 A COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF ATHEROSCLEROSIS 

 

																	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	 Inventor

	 01/21558
	  	PCT	  	04-Oct-1998
 126447
	  	01-Apr-2001	  	30-Sep-1999
 IL99/00519
	  	Publ. Date: 13-Apr-2000
 Publ. #:
WO00/20019
	 		  	Expired	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 01/21884
	  	Europe
 NP
	  	04-Oct-1998
 126447
	  		  	30-Sep-1999
 99970026.3
	  	14-May-2003
 1126867
	 		  	Granted	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 01/21886
	  	Canada
 NP
	  	04-Oct-1998
 126447
	  		  	30-Sep-1999
 2,345,445
	  	24-Aug-2010
 2,345,445
	 		  	Granted	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 01/21887
	  	Australia
 NP
	  	04-Oct-1998
 126447
	  		  	30-Sep-1999
 59966/99
	  	28-Aug-2003
 760582
	 		  	Granted	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 01/21888
	  	China
 NP
	  	04-Oct-1998
 126447
	  	04-Apr-2001	  	30-Sep-1999
 99814030.9
	  	24-Nov-2004
 ZL99814030.9
	 		  	Granted	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 02/23904
	  	Hong Kong
 NP
	  	04-Oct-1998
 126447
	  	19-Jul-2002	  	30-Sep-1999
 02105365.4
	  	18-Nov-2005
 HK1043743
	 		  	Granted	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 28590
	  	China
 DIV
	  	04-Oct-1998
 126447
	  	23-Sep-2004	  	30-Sep-1999
 200410011940.7
	  	05-Nov-2008
 ZL200410011940.7
	 		  	Granted	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 30562
	  	Hong Kong
 DIV
	  	04-Oct-1998
 126447
	  	28-Sep-2005	  	30-Sep-1999
 05108561.7
	  	21-Aug-2009
 HK1076600
	 		  	Granted	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 01/21889
	  	Singapore
 NP
	  	04-Oct-1998
 126447
	  		  	30-Sep-1999
 200101998-3
	  	30-Apr-2003
 80182
	 		  	Granted	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

  
 27 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 01/21890
	  	Japan
 NP
	  	04-Oct-1998
 126447
	  		  	30-Sep-1999
 2000-573378
	  		  		  	Pending	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 01/21891
	  	Hungary
 NP
	  	04-Oct-1998
 126447
	  	30-Sep-1999	  	30-Sep-1999
 P0104410
	  		  		  	Pending	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 [* * *]
	  		  		  		  		  		  		  		  	
	 01/21893
	  	Republic of Korea
 NP
	  	04-Oct-1998
 126447
	  		  	30-Sep-1999
 2001-7004285
	  	02-Feb-2007
 680707
	  		  	Granted	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 01/21885
	  	USA
 NP
	  	04-Oct-1998
 126447
	  	30-Mar-2001	  	30-Sep-1999
 09/806,400
	  		  		  	Abandoned	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 01/22498
	  	USA
 CON
	  	04-Oct-1998
 126447
	  	04-Sep-2001	  	30-Sep-1999
 09/944,592
	  		  		  	Abandoned	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	  
 COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I FOR THE
PREVENTION AND/OR TREATMENT OF VASCULAR DISEASE
  

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	 Inventor

	 28919
	  	USA
 CIP
	  	04-Oct-1998
 126447
	  		  	15-Apr-2005
 11/106,665
	  		  		  	Abandoned	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE Jacob;

YACOV Niva

  
 28 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

 METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF
ATHEROSCLEROSIS 
  

																	
	 Our Ref
	  	Country	  	Earliest
      Priority      	  	      Entry Date      	  	Filing Date
  Application No.  	  	Issue Date
    Patent No.    	  	SKGF Ref	  	Status	  	 Inventor

	 26038
	  	USA
 CIP
	  	22-Nov-2000
 60/252,574
	  		  	27-May-2003
 10/445,347
	  	04-Jan-2005
 6,838,452
	  		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti; YACOV Niva

	 27041
	  	USA
 DIV
	  	24-Nov-2000
 60/252,574
	  	24-Nov-2003	  	27-May-2003
 10/718,596
	  	06-Mar-2007
 7,186,704
	  		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 29890
	  	USA
 DIV
	  	24-Nov-2000
 60/252,574
	  	19-Jul-2005	  	27-May-2003
 11/183,884
	  	17-Mar-2009
 7,504,388
	  		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 45347
	  	USA
 DIV
	  	24-Nov-2000
 60/252,574
	  	17-Feb-2009	  	27-May-2003
 12/371,930
	  	22-Feb-2011
 7,893,291
	  		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 50439
	  	USA
 CON
	  	24-Nov-2000
 60/252,574
	  	06-Jan-2011	  	27-May-2003
 12/985,365
	  	17 April
 20128,158,611
	  		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 53355
	  	USA
 CON
	  	24-Nov-2000
 60/252,574
	  	March 27, 2012	  	27-May-2003
 13/431,262
	  		  		  	Pending	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV
Niva

  
 29 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	  
 OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF
INFLAMMATORY DISEASES AND DISORDERS
  

	 Our Ref
	 	Country	  	    Earliest Priority    	  	      Entry Date      	  	Filing Date
  Application No.  	  	Issue Date
    Patent No.    	 	SKGF Ref	  	Status	  	 Inventor

	 27909
	 	PCT	  	27-May-2003
 10/445,347
	  		  	27-May-2004
 IL2004/000453
	  	Publ. Date: 09-Dec-2004

Publ. #: WO2004/106486
	 		  	Expired	  	 HARATS Dror; GEORGE
 Jacob;
HALPERIN Gideon

	 31532
	 	USA
 NP
	  	27-May-2003
 10/445,347
	  	25-Apr-2008	  	27-May-2004
 10/567,543
	  	08-Mar-2011
 7,902,176
	 		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN
Gideon;
 KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 30958
	 	Mexico
 NP
	  	27-May-2003
 10/445,347
	  	25-Nov-2005	  	27-May-2004
 pa/A/2005/012784
	  	14-Oct-2008
 261341
	 		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN
Gideon

	 [* * *]
	 		  		  		  		  		 		  		  	
	 30947
	 	Europe
 NP
	  	27-May-2003
 10/445,347
	  	07-Dec-2005	  	27-May-2004
 04735088.9
	  		 		  	Pending	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 32340
	 	Hong Kong
 NP
	  	27-May-2003
 10/445,347
	  	03-Aug-2006	  	27-May-2004
 06108608.1
	  		 		  	Pending	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 30948
	 	Japan
 NP
	  	27-May-2003
 10/445,347
	  	30-Nov-2005	  	27-May-2004
 2006-531006
	  		 		  	Pending	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 [* * *]
	 		  		  		  		  		 		  		  	
	 30949
	 	Canada
 NP
	  	27-May-2003
 10/445,347
	  	28-Nov-2005	  	27-May-2004
 2,527,483
	  		 		  	Pending	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 30950
	 	China
 NP
	  	27-May-2003
 10/445,347
	  	01-Nov-2005	  	27-May-2004
 200480021217.5
	  	22-Dec-2010
 ZL200480021217.5
	 		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV
Niva

  
 30 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 49865
	 	China
 DIV
	  	27-May-2003
 10/445,347
	  	25-Oct-2010	  	27-May-2004
 201010537971.1
	  		  		  	Pending	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN
Gideon;
 KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 30951
	 	Australia
 NP
	  	27-May-2003
 10/445,347
	  	13-Dec-2005	  	27-May-2004
 2004243695
	  	17-Mar-2011
 2004243695
	  		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 30952
	 	Republic of Korea
 NP
	  	27-May-2003
 10/445,347
	  	28-Nov-2005	  	27-May-2004
 2005-7022741
	  	3-Nov 2011
 1081977
	  		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 50809
	 	Republic of Korea
 DIV
	  	27-May-2003
 10/445,347
	  	18-Feb-2011	  	27-May-2004
 2011-7003840
	  	23 Feb 2012
 10-1122160
	  		  	Pending	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 30953
	 	New Zealand
 NP
	  	27-May-2003
 10/445,347
	  	01-Dec-2005	  	27-May-2004
 544285
	  	12-Mar-2009
 544285
	  		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 30954
	 	South Africa
 NP
	  	27-May-2003
 10/445,347
	  	01-Dec-2005	  	27-May-2004
 2005/09929
	  	27-Dec-2006
 2005/9929
	  		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 30955
	 	India
 NP
	  	27-May-2003
 10/445,347
	  	27-Dec-2005	  	27-May-2004
 3555/CHENP/2005
	  	26-Mar-2009
 232654
	  		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 [* * *]
	 		  		  		  		  		  		  		  	

  
 31 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 [* * *]
	 		  		  		  		  		 		  		  	
	 30957
	 	Russian Federation
 NP
	  	27-May-2003
 10/445,347
	  	01-Dec-2005	  	27-May-2004
 2005140666
	  	27-Jul-2009
 2362567
	 		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 46052
	 	Russian Federation
 DIV
	  	27-May-2003
 10/445,347
	  	06-Apr-2009	  	27-May-2004
 2009112686
	  		 		  	Pending	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	  
 OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES
THEREOF
  

	 Our Ref
	 	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	 Inventor

	 [* * *]
	 		  		  		  		  		 		  		  	
	 46530
	 	PCT	  	08-Oct-2008
 61/103,571
	  		  	01-Oct-2009
 IL2009/000949
	  	Publ. Date: 15-Apr-2010

Publ. #: WO2010/041242
	 		  	Expired	  	 HALPERIN Gideon;
 KOVALEVSKI-ISHAI Eti;

BREITBART Eyal; MENDEL
 Itzhak; ZINIUK Zeev; FEIGE
Erez

	 50053
	 	USA
 NP
	  	08-Oct-2008
 61/103,571
	  	06-Apr-2011	  	01-Oct-2009
 13/122,766
	  		 		  	Pending	  	 HALPERIN Gideon;
 KOVALEVSKI-ISHAI Eti;

BREITBART Eyal; MENDEL
 Itzhak; ZINIUK Zeev; FEIGE
Erez

	 50054
	 	Europe
 NP
	  	08-Oct-2008
 61/103,571
	  	20-Apr-2011	  	01-Oct-2009
 09818874.1
	  		 		  	Pending	  	 HALPERIN Gideon;
 KOVALEVSKI-ISHAI Eti;

BREITBART Eyal; MENDEL
 Itzhak; ZINIUK Zeev; FEIGE
Erez

  
 32 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 50055
	 	Israel
 NP
	  	08-Oct-2008
 61/103,571
	  	05-Apr-2011	  	01-Oct-2009
 212153
	  		 		  	Pending	  	 HALPERIN Gideon;
 KOVALEVSKI-ISHAI Eti;

BREITBART Eyal; MENDEL
 Itzhak; ZINIUK Zeev; FEIGE

Erez

	  
 COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I-DERIVED
PEPTIDES FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISEASE
  

	 Our Ref
	 	Country	  	      Earliest Priority      	  	      Entry Date      	  	Filing Date
  Application No.  	  	Issue Date
    Patent No.    	 	SKGF Ref	  	Status	  	 Inventor

	 [* * *]
	 		  		  		  		  		 		  		  	
	 31865
	 	PCT	  	15-Apr-2005
 60/671,500
	  		  	11-Apr-2006
 IL2006/000467
	  	Publ. Date: 19-Oct-2006

Publ. #: WO2006/109312
	 		  	Expired	  	 YACOV Niva; BREITBART
 Eyal

	 41853
	 	Europe
 NP
	  	15-Apr-2005
 60/671,500
	  	24-Oct-2007	  	11-Apr-2006
 06728268.1
	  		 		  	Abandoned	  	 YACOV Niva; BREITBART
 Eyal

	 41854
	 	USA
 NP
	  	15-Apr-2005
 60/671,500
	  	10-Oct-2007	  	11-Apr-2006
 11/918,141
	  		 		  	Abandoned	  	 YACOV Niva; BREITBART
 Eyal

	 [* * *]
	 		  		  		  		  		 		  		  	
	 [* * *]
	 		  		  		  		  		 		  		  	

 NOVEL DERIVATIVES OF OXIDIZED PHOSPHOLIPIDS 

  
 33 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
									
	 [* * *]
	  		  		  		  		  		 		  		  	
	
	OXIDIZED LIPID COMPOUNDS AND USES THEREOF
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 45018
	  	PCT	  	06-Nov-2008
 61/193,220
	  		  	05-Nov-2009
 IL2009/001049
	  	Publ. Date: 14-May-2010

Publ. #: WO2010/052718
	 		  	Expired	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez
	 50603
	  	USA
 NP
	  	06-Nov-2008
 61/193,220
	  	05-May-2011	  	05-Nov-2009
 13/127,717
	  		 		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez
	 [* * *]
	  		  		  		  		  		 		  		  	
	 50605
	  	Europe
 NP
	  	06-Nov-2008
 61/193,220
	  	16-May-2011	  	05-Nov-2009
 09824498.1
	  		 		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez
	 51983
	  	Hong Kong
 NP
	  		  		  	05-Nov-2009	  		 		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez

  
 34 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 50606
	  	Canada
 NP
	  	06-Nov-2008
 61/193,220
	  	13-Apr-2011	  	05-Nov-2009
 2,740,726
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez
	 [* * *]
	  		  		  		  		  		  		  		  	
	 50608
	  	Australia
 NP
	  	06-Nov-2008
 61/193,220
	  	15-Apr-2011	  	05-Nov-2009
 2009312355
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez
	 50609
	  	New Zealand
 NP
	  	06-Nov-2008
 61/193,220
	  	19-Apr-2011	  	05-Nov-2009
 592357
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez
	 [* * *]
	  		  		  		  		  		  		  		  	
	 50611
	  	Japan
 NP
	  	06-Nov-2008
 61/193,220
	  	06-May-2011	  	05-Nov-2009	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez
	 50612
	  	Republic of Korea
 NP
	  	06-Nov-2008
 61/193,220
	  	02-Jun-2011	  	05-Nov-2009
 2011-7012700
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez

  
 35 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 50613
	  	Mexico
 NP
	  	06-Nov-2008
 61/193,220
	  	04-May-2011	  	05-Nov-2009
 MX/a/2011/004773
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez
	 50614
	  	Russian Federation
 NP
	  	06-Nov-2008
 61/193,220
	  	06-Jun-2011	  	05-Nov-2009
 2011122729
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez
	 50615
	  	China
 NP
	  	06-Nov-2008
 61/193,220
	  	30-Jun-2011	  	05-Nov-2009
 200980153378.2
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez

 ENDOTHELIAL-SPECIFIC APOPTOSIS INDUCED BY AN ADENOVIRAL VECTOR CONTAINING A CHIMERIC RECEPTOR DRIVEN BY A TISSUE SPECIFIC
PROMOTER 
  

																	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	 Issue Date

Patent No.
	  	SKGF Ref	  	Status	  	Inventor
									
	 [* * *]
	  		  		  		  		  		  		  		  	
	
	POLYNUCLEOTIDE CONSTRUCTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TARGETED DOWNREGULATION OF ANGIOGENESIS AND ANTICANCER THERAPY
									
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	 Issue Date

Patent No.
	  	SKGF Ref	  	Status	  	Inventor
	 02/23346
	  	PCT	  	19-Oct-2001
 60/330,118
	  		  	01-May-2002
 IL02/00339
	  	 Publ. Date: 24-Apr-2003

Publ. #: WO03/033514
	  		  	Expired	  	HARATS Dror;
GREENBERGER Shoshana
	 27526
	  	USA
 NP
	  	19-Oct-2001
 60/330,118
	  	12-Apr-2004	  	01-May-2002
 10/490,746
	  	 08-Sep-2009
 7,585,666
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

  
 36 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 44506
	  	USA
 DIV
	  	19-Oct-2001
 60/330,118
	  	08-Aug-2008	  	01-May-2002
 12/222,439
	  	 02-Aug-2011
 7,989,427
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 51506
	  	USA
 DIV
	  	19-Oct-2001
 60/330,118
	  	20-Jun-2011	  	01-May-2002
 13/163,767
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 27527
	  	Europe
 NP
	  	19-Oct-2001
 60/330,118
	  	21-Apr-2004	  	01-May-2002
 02801473.6
	  	 22-Sep-2010
 1436313
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 29028
	  	Hong Kong
 NP
	  	19-Oct-2001
 60/330,118
	  	06-Jan-2005	  	01-May-2002
 05100081.5
	  	 01-Apr-2011
 HK1067641
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 49785
	  	Europe
 DIV
	  	19-Oct-2001
 60/330,118
	  	17-Sep-2010	  	01-May-2002
 EP10177257.2
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 47553
	  	Europe
 DIV
	  	19-Oct-2001
 60/330,118
	  	18-Nov-2009	  	01-May-2002
 09176343.3
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 49931
	  	Hong Kong
 DIV
	  	19-Oct-2001
 60/330,118
	  	10-Dec-2010	  	01-May-2002
 10111522.2
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 51004
	  	Hong Kong
 DIV
	  	19-Oct-2001
 60/330,118
	  	27-Apr-2011	  	01-May-2002
 11104228.3
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 27528
	  	Japan
 NP
	  	19-Oct-2001
 60/330,118
	  	16-Apr-2004	  	01-May-2002
 2003-536253
	  	 22-Aug-2008
 4,173,446
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

  
 37 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 27529
	  	Republic of Korea
 NP
	  	19-Oct-2001
 60/330,118
	  	17-Apr-2004	  	01-May-2002
 2004-7005720
	  	 24-Oct-2008
 866117
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 27530
	  	India
 NP
	  	19-Oct-2001
 60/330,118
	  	19-Apr-2004	  	01-May-2002
 801/CHENP/2004
	  	 26-Dec-2008
 226357
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 27531
	  	China
 NP
	  	19-Oct-2001
 60/330,118
	  	09-Jun-2004	  	01-May-2002
 02824547.4
	  	 01-Jul-2009
 ZL02824547.4
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 46077
	  	China
 DIV
	  	19-Oct-2001
 60/330,118
	  	27-Apr-2009	  	01-May-2002
 200910137707.6
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 27532
	  	Singapore
 NP
	  	19-Oct-2001
 60/330,118
	  	16-Apr-2004	  	01-May-2002
 200402237-2
	  	 31-May-2006
 103725
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 27533
	  	Canada
 NP
	  	19-Oct-2001
 60/330,118
	  	16-Apr-2004	  	01-May-2002
 2,463,816
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 27534
	  	Mexico
 NP
	  	19-Oct-2001
 60/330,118
	  	19-Apr-2004	  	01-May-2002
 PA/a/2004/003514
	  	 12-Nov-2010
 280956
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 [* * *]
	  		  		  		  		  		  		  		  	
	 27535
	  	Australia
 NP
	  	19-Oct-2001
 60/330,118
	  	20-Apr-2004	  	01-May-2002
 2002307793
	  	 17-May-2007
 2002307793
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 27536
	  	New Zealand
 NP
	  	19-Oct-2001
 60/330,118
	  	16-Apr-2004	  	01-May-2002
 532348
	  	 12-Oct-2006
 532348
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 27537
	  	South Africa
 NP
	  	19-Oct-2001
 60/330,118
	  	08-Apr-2004	  	01-May-2002
 2004/2756
	  	 31-May-2006
 2004/02756
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal

  
 38 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

 USING A MINI-GENE CONSTRUCT (3X-PPR-1) FOR ENDOTHELIAL CELLS SPECIFIC GENE THERAPY. IMPLICATIONS IN
CARDIOVASCULAR, CANCER AND WOUND HEALING 
  

																	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
		  		  		  		  		  		 		  		  	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 01/22752
	  	PCT	  	17-Nov-2000
 60/248,582
	  		  	15-Nov-2001
 IL01/01059
	  	Publ. Date: 23-May-2002
 Publ. #:
WO02/40629
	 		  	Expired	  	HARATS Dror
	 26025
	  	Europe
 NP
	  	17-Nov-2000
 60/248,582
	  	15-May-2003	  	15-Nov-2001
 01996590.4
	  	20-Jan-2010
 1443970
	 		  	Granted	  	HARATS Dror; BLOOM Nira
	 29027
	  	Hong Kong
 NP
	  	17-Nov-2000
 60/248,582
	  	12-Jan-2005	  	15-Nov-2001
 05100240.3
	  	20-Aug-2010
 HK1068057
	 		  	Granted	  	HARATS Dror; BLOOM Nira
	 47088
	  	Europe
 DIV
	  	17-Nov-2000
 60/248,582
	  	04-Nov-2009	  	15-Nov-2001
 09174998.6
	  		 		  	Pending	  	HARATS Dror; BLOOM Nira
	 49806
	  	Europe
 DIV
	  	17-Nov-2000
 60/248,582
	  	01-Oct-2010	  	15-Nov-2001
 EP10185193.9
	  		 		  	Pending	  	HARATS Dror; BLOOM Nira
	 49498
	  	Hong Kong
 DIV
	  	17-Nov-2000
 60/248,582
	  	13-Oct-2010	  	15-Nov-2001
 10109698.4
	  		 		  	Pending	  	HARATS Dror; BLOOM Nira

  
 39 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 52630
	  	Hong Kong
 DIV
	  	17-Nov-2000
 60/248,582
	  	2-Dec-2011	  	15-Nov-2001
 11113094.5
	  		  	3182.034HK21	  	Pending	  	HARATS Dror; BLOOM Nira
	 26026
	  	Israel
 NP
	  	17-Nov-2000
 60/248,582
	  	15-May-2003	  	15-Nov-2001
 155940
	  	30-Mar-2009
 155940
	  		  	Granted	  	HARATS Dror; BLOOM Nira
	 26027
	  	India
 NP
	  	17-Nov-2000
 60/248,582
	  	14-May-2003	  	15-Nov-2001
 743/CHENP/2003
	  	20-Nov-2007
 211599
	  		  	Granted	  	HARATS Dror; BLOOM Nira
	 26028
	  	USA
 NP
	  	17-Nov-2000
 60/248,582
	  	16-May-2003	  	15-Nov-2001
 10/416,917
	  		  		  	Abandoned	  	HARATS Dror
	 26029
	  	Canada
 NP
	  	17-Nov-2000
 60/248,582
	  	15-May-2003	  	15-Nov-2001
 2,429,342
	  		  		  	Pending	  	HARATS Dror; BLOOM Nira
	 26030
	  	Australia
 NP
	  	17-Nov-2000
 60/248,582
	  	15-May-2003	  	15-Nov-2001
 2002224002
	  	26-Jul-2007
 2002224002
	  		  	Abandoned	  	HARATS Dror
	 28653
	  	Australia
 DIV
	  	17-Nov-2000
 60/248,582
	  	01-Dec-2004	  	15-Nov-2001
 2003222427
	  	09-Sep-2010
 2003222427
	  		  	Granted	  	HARATS Dror; BREITBART
Eyal; BLOOM Nira
	 49098
	  	Australia
 DIV
	  	15-Nov-2001
 2002224002
	  	25-Jun-2010	  	15-Nov-2001
 2010202660
	  	1-Dec 2011
 2010202660
	  		  	Granted	  	HARATS Dror; BREITBART
Eyal; BLOOM Nira
	 26031
	  	Japan
 NP
	  	17-Nov-2000
 60/248,582
	  	16-May-2003	  	15-Nov-2001
 2002-543626
	  	16-Jan-2009
 4,243,653
	  		  	Granted	  	HARATS Dror; BLOOM Nira
	 26032
	  	China
 NP
	  	17-Nov-2000
 60/248,582
	  	16-Jul-2003	  	15-Nov-2001
 01822075.4
	  	04-Feb-2009
 ZL0182275.4
	  		  	Granted	  	HARATS Dror; BLOOM Nira

  
 40 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

															
	 26033
	  	Republic of Korea
 NP
	  	17-Nov-2000
 60/248,582
	  	17-May-2003	  	15-Nov-2001
 2003-7006728
	  	14-Nov-2008
 869814
	  	Granted	  	HARATS Dror
	 44105
	  	Republic of Korea
 DIV
	  	17-Nov-2000
 60/248,582
	  	28-Jul-2008	  	15-Nov-2001
 2008-7018598
	  	10-Sep-2009
 917854
	  	Granted	  	HARATS Dror;  BLOOM Nira
	 26034
	  	Mexico
 NP
	  	17-Nov-2000
 60/248,582
	  	16-May-2003	  	15-Nov-2001
 PA/a/2003/004325
	  	15-Aug-2008
 259670
	  	Granted	  	HARATS Dror

 COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I FOR THE PREVENTION AND/OR TREATMENT OF ATHEROSCLEROSIS 

 

																	
	 Our Ref
	  	 Country
	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	 Inventor

	 28918
	  	 USA
 CIP
	  	04-Oct-1998
 126447
	  		  	17-Nov-2004
 10/989,724
	  		  		  	Abandoned	  	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva

 COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISEASE 

 

																	
	 Our Ref
	  	 Country
	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	 Inventor

	 30236
	  	PCT	  	17-Nov-2004
 10/989,724
	  		  	25-Sep-2005
 IL2005/001022
	  	Publ. Date:
 26-May-2006

Publ. #: |WO2006/054281
	  		  	Expired	  	 HARATS Dror;
 SHOENFELD Yehuda;

GEORGE Jacob; YACOV Niva

	 39233
	  	 Europe
 NP
	  	17-Nov-2004
 10/989,724
	  	13-Jun-2007	  	25-Sep-2005
 05788473.6
	  		  		  	Abandoned	  	 HARATS Dror;
 SHOENFELD Yehuda;

GEORGE Jacob; YACOV Niva

	 42004
	  	 Hong Kong
 NP
	  	17-Nov-2004
 10/989,724
	  		  	12-Sep-2007
 07109873.6
	  		  		  	Abandoned	  	 HARATS Dror;
 SHOENFELD Yehuda;

GEORGE Jacob; YACOV Niva

  
 41 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

 PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS

  

																	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
	 28376
	  	USA
 CIP
	  	17-Nov-2000
 60/248,582
	  		  	14-Nov-2004
 10/988,487
	  	6-Dec 2011
 8,071,740
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 50225
	  	USA
 DIV
	  	17-Nov-2000
 60/248,582
	  	01-Feb-2011	  	14-Nov-2004
 13/018,447
	  	26-June 2012
 8,206,743
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 50927
	  	USA
 DIV
	  	17-Nov-2000
 60/248,582
	  	02-May-2011	  	14-Nov-2004
 13/098,512
	  		  		  	Aban	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 47407
	  	USA
 DIV
	  	17-Nov-2000
 60/248,582
	  	13-Nov-2009	  	14-Nov-2004
 12/591,252
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 60001
	  	USA
 Con
	  	17-Nov-2000
 60/248,582
	  	13-July 2012	  	14-Nov-2004
 13/549,355
	  		  	3182.0370004	  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 30269
	  	PCT	  	14-Nov-2004	  		  	14-Nov-2005	  	Publ. Date: 18-May-2006	  		  	Expired	  	HARATS Dror;
GREENBERGER Shoshana

  
 42 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

															
		  		  	10/988,487	  		  	IL2005/001195	  	Publ. #: WO2006/051545	 		  	
	 [* * *]
	  		  		  		  		  		 		  	
	 [* * *]
	  		  		  		  		  		 		  	
	 47087
	  	Europe
 DIV
	  	14-Nov-2004
 10/988,487
	  	28-Aug-2009	  	14-Nov-2005
 09168899.4
	  	2 Nov 2011
 2174668
	 	Grnated	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 49224
	  	Hong Kong
 DIV
	  		  	12-Oct-2010	  	14-Nov-2005
 10109638.7
	  	15 June 2012
 HK1143078
	 	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 49804
	  	Europe
 DIV
	  	14-Nov-2004
 10/988,487
	  	01-Oct-2010	  	14-Nov-2005
 EP10185195.4
	  	26 Sep 2012
 2301586
	 	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 49805
	  	Europe
 DIV
	  	14-Nov-2004
 10/988,487
	  	30-Sep-2010	  	14-Nov-2005
 EP10184033.8
	  		 	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 39318
	  	Australia
 NP
	  	14-Nov-2004
 10/988,487
	  	08-Jun-2007	  	14-Nov-2005
 2005303385
	  		 	Allowed	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 51825
	  	Australia
 DIV
	  	14-Nov-2004
 10/988,487
	  		  	14-Nov-2005	  	28 June 2012
 2011205076
	 	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 53691
	  	Australia	  	14-Nov-2004	  	15 June 2012	  	14-Nov-2005	  		 	Pending	  	HARATS Dror;
GREENBERGER Shoshana;

  
 43 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

															
		  	DIV	  	10/988,487	  		  	2012203578	  		  		  	BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 39323
	  	New Zealand
 NP
	  	14-Nov-2004
 10/988,487
	  	05-Jun-2007	  	14-Nov-2005
 555612
	  	08-Apr-2010
 555612
	  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 47297
	  	New Zealand
 DIV
	  	14-Nov-2004
 10/988,487
	  	09-Oct-2009	  	14-Nov-2005
 580289
	  	05-Apr-2011
 580289
	  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 39324
	  	South Africa
 NP
	  	14-Nov-2004
 10/988,487
	  	05-Jun-2007	  	14-Nov-2005
 2007/04687
	  	31-Dec-2008
 2007/04687
	  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat
	 [* * *]
	  		  		  		  		  		  		  	
	 50629
	  	Singapore
 DIV
	  	14-Nov-2004
 10/988,487
	  	11-Apr-2011	  	14-Nov-2005
 201102612-7
	  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat
	 39315
	  	Israel
 NP
	  	14-Nov-2004
 10/988,487
	  	14-May-2007	  	14-Nov-2005
 183187
	  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 50104
	  	Israel
 DIV
	  	14-Nov-2004
 10/988,487
	  	31-Oct-2010	  	14-Nov-2005
 209034
	  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat
	 [* * *]
	  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  	

  
 44 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 39317
	  	Canada
 NP
	  	14-Nov-2004
 10/988,487
	  	17-May-2007	  	14-Nov-2005
 2,587,469
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 39319
	  	Japan
 NP
	  	14-Nov-2004
 10/988,487
	  	14-May-2007	  	14-Nov-2005
 2007-540833
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 52137
	  	Japan
 Div
	  	14-Nov-2004
 10/988,487
	  	Sep 2011	  	14-Nov-2005
 2011-191492
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 39320
	  	China
 NP
	  	14-Nov-2004
 10/988,487
	  	13-Aug-2007	  	14-Nov-2005
 200580046412.8
	  		  		  	Aban	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 39321
	  	Republic
 of KoreaNP
	  	14-Nov-2004
 10/988,487
	  	14-Jun-2007	  	14-Nov-2005
 2007-7013464
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 39322
	  	Mexico
 NP
	  	14-Nov-2004
 10/988,487
	  	11-May-2007	  	14-Nov-2005
 MX/a/2007/005783
	  	8 May 2012
 299008
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat
	 52598
	  	Mexico
 Div
	  	14-Nov-2004
 10/988,487
	  		  	14-Nov-2005	  	4 Sep 2012
 303042
	  	3182.037MX11	  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat
	 [* * *]
	  		  		  		  		  		  		  		  	

  
 45 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 Method for treating vascular inflammation and psoriasis

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	

  

																	
	 Treatment Of Inflammation
  

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 53305
	  	PCT	  	12 Dec 2011
 61/569,545 and
 12 Dec
2011
 61/569,481
	  		  	11 Dec 2012
 PCT/US2012/068995
	  		  	3182.014PC01	  	Pending	  	MENDEL, Itzhak;
 FEIGE, Erez;
 YACOV, Niva;

PROPHETE-MEIRAN, Oshrat;
BREITBART, Eyal;

SALEM, Yaniv

  
 46 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

																	
	 Treatment Methods Using Adenovirus

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		  		  		  	

  

																	
	 TARGETED GENE EXPRESSION USING PREPROENDOTHELIN-1 PROMOTERS

 

	 Our
Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
	 N/A
	  	USA CIP	  	03-Mar-1994
 08/254,015
	  		  	28-Feb-1995
 08395742
	  	05-May-1998
 5747340
	  	Originally assinged to Syntex
USA. Licensed to VBL	  	Granted	  	HARATS Dror;
 KURIHARA Hiroki;

NANETTE BELLONI Paula; SIGAL
Charles Elliott

  

																	
	 METHOD AND COMPOSITION TO INCREASE RADIATION-INDUCED TUMOR THERAPEUTIC EFFECTS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	 SKGF Ref
	  	Status	  	Inventor
	 N/A
	  	PCT	  	08-Dec-2009
 61/283,696
	  		  	07-Dec-2010
 US2010/059204
	  	Publ. Date: 16-Jun-2011

Publ. #: WO/2011/071859
	 	As of June 2012, the applicant is also VBL	  	Pending	  	KOLESNICK, Richard, N.
 STANCEVIC, Branka;

SADELAIN, Michel;
 FUKS, Zvi;

VARDA-BLOOM, Nira;
 HARATS, Dror;

  
 47 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

															
	 Trademark: VBL therapeutics & logo

 

	 Our Ref

Client Ref
	  	Country	 	Class	  	Earliest
Priority	  	Filing Date
Application No.	  	Registration Date
Registration No.	  	SKGF Ref	  	Status
	 47638
	  	Europe	 	5, 42 & 44	  		  	03-Dec-2009
 008730541
	  	02-Jun-2010
 008730541
	  		  	Registered
	  
 Trademark: VASCULAR BIOGENICS

 

	 Our Ref

Client Ref
	  	Country	 	Class	  	Earliest
Priority	  	Filing Date
Application No.	  	Registration Date
Registration No.	  	SKGF Ref	  	Status
	 42092
	  	Israel	 	42	  		  	23-Aug-2007
 203346
	  	06-May-2009
 203346
	  		  	Registered
	 43074
	  	USA
 (Paris)
	 	42	  	23-Aug-2007
 203346
	  	14-Feb-2008
 77/397,305
	  	22-Jun-2010
 3,805,239
	  		  	Registered
	 43075
	  	Europe
 (Paris)
	 	5, 42 & 44	  	23-Aug-2007
 203346
	  	18-Feb-2008
 006675599
	  	20-Feb-2009
 006675599
	  		  	Registered

  
 48 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

 Trademark: VBL VASCULAR BIOGENICS LTD. & Device 

 

															
	 Our Ref

Client Ref
	  	Country	 	Class	  	Earliest
Priority	  	Filing Date
Application No.	  	Registration Date
Registration No.	  	SKGF Ref	  	Status
	 42199
	  	Israel	 	42	  		  	09-Sep-2007
 203748
	  	10-May-2009
 203748
	  		  	Registered
	 43602
	  	USA
 (Paris)
	 	42	  	09-Sep-2007
 203748
	  	03-Mar-2008
 77/411,204
	  	22-Jun-2010
 3,805,245
	  		  	Registered
	 43603
	  	Europe
 (Paris)
	 	42	  	09-Sep-2007
 203748
	  	04-Mar-2008
 006721823
	  	04-Sep-2009
 006721823
	  		  	Registered
	  
 Trademark: VTS

 

	 Our Ref

Client Ref
	  	Country	 	Class	  	Earliest
Priority	  	Filing Date
Application No.	  	Registration Date
Registration No.	  	SKGF Ref	  	Status
	 42198
	  	Israel	 	5	  		  	09-Sep-2007
 203747
	  	06-May-2009
 203747
	  		  	Registered
	 43600
	  	USA
 (Paris)
	 	5	  	09-Sep-2007
 203747
	  	03-Mar-2008
 77/411,151
	  	20-Oct-2009
 3,697,519
	  		  	Registered
	 43601
	  	Europe
 (Paris)
	 	5	  	09-Sep-2007
 203747
	  	04-Mar-2008
 006721484
	  	20-Feb-2009
 006721484
	  		  	Registered

  
 49 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

 Trademark: VASCULAR TARGETING SYSTEM VTS 

 

															
	 Our Ref

Client Ref
	  	Country	 	Class	  	Earliest
Priority	  	Filing Date
Application No.	  	Registration Date
Registration No.	  	SKGF Ref	  	Status
	 41864
	  	Israel	 	5	  		  	23-Aug-2007
 203345
	  	08-Sep-2009
 203345
	  		  	Registered
	 43072
	  	USA
 (Paris)
	 	5	  	23-Aug-2007
 203345
	  	14-Feb-2008
 77/397,328
	  	18-May-2010
 3,789,108
	  		  	Registered
	 43073
	  	Europe
 (Paris)
	 	5, 42 & 44	  	23-Aug-2007
 203345
	  	18-Feb-2008
 006675896
	  	29-Jan-2009
 006675896
	  		  	Registered

  
 50 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

															
	 Trademark: VBL
  

	 Our Ref

Client Ref
	  	Country	 	Class	  	Earliest
Priority	  	Filing Date
Application No.	  	Registration Date
Registration No.	  	SKGF Ref	  	Status
	 42093
	  	Israel	 	42	  		  	23-Aug-2007
 203347
	  	22-Jan-2009
 203347
	  		  	Registered
	 43076
	  	USA
 (Paris)
	 	42	  	23-Aug-2007
 203347
	  	14-Feb-2008
 77/397,293
	  	14-Jul-2009
 3,653,176
	  		  	Registered
	 43077
	  	Europe
 (Paris)
	 	5, 42 & 44	  	23-Aug-2007
 203347
	  	18-Feb-2008
 006673263
	  	22-Jan-2009
 006673263
	  		  	Registered
	  
 Trademark: VBL therapeutics & logo

 

	 Our Ref

Client Ref
	  	Country	 	Class	  	Earliest
Priority	  	Filing Date
Application No.	  	Registration Date
Registration No.	  	SKGF Ref	  	Status
	 47612
	  	Israel	 	42	  		  	30-Nov-2009
 225329
	  	07-Feb-2011
 225329
	  		  	Registered
	 47639
	  	USA
 (Paris)
	 	42	  	30-Nov-2009
 225329
	  	26-Apr-2010
 85/023,397
	  	24-May-2011
 3,964,829
	  		  	Registered

  
 51 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

 Domains: VBL 

vascularbiogenics.com 
 vascularbiogenicsltd.com 

vbl-therapeutics.com 
 vbltherapeutics.com 

vbltx.com 
 vascularbiogenics.net 

vbl.co.il 
 vblrx.com 

vascular-biogenics.com 

  
 52 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}]]